###begin article-title 0
###xml 18 22 18 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
Activation of 5-HT2A/C Receptors Counteracts 5-HT1A Regulation of N-Methyl-D-aspartate Receptor Channels in Pyramidal Neurons of Prefrontal Cortex*
###end article-title 0
###begin p 1
###xml 239 258 239 258 <email xmlns:xlink="http://www.w3.org/1999/xlink">zhenyan@buffalo.edu</email>
 To whom correspondence should be addressed: Dept. of Physiology and Biophysics, School of Medicine and Biomedical Sciences, State University of New York, 124 Sherman Hall, Buffalo, NY 14214. Tel.: 716-829-3058; Fax: 716-829-2699; E-mail: zhenyan@buffalo.edu. 
###end p 1
###begin p 2
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 2
###begin p 3
 applies to Author Choice Articles
###end p 3
###begin p 4
###xml 296 298 296 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 327 328 327 328 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 487 491 487 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 545 547 545 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 632 636 632 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 644 646 644 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 803 807 803 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 982 986 979 983 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1041 1045 1038 1042 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1053 1055 1050 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1129 1133 1126 1130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1181 1183 1178 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1343 1345 1337 1339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1354 1358 1348 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1452 1456 1446 1450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1533 1535 1524 1526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
Abnormal serotonin-glutamate interaction in prefrontal cortex (PFC) is implicated in the pathophysiology of many mental disorders, including schizophrenia and depression. However, the mechanisms by which this interaction occurs remain unclear. Our previous study has shown that activation of 5-HT1A receptors inhibits N-methyl-d-aspartate (NMDA) receptor (NMDAR) currents in PFC pyramidal neurons by disrupting microtubule-based transport of NMDARs. Here we found that activation of 5-HT2A/C receptors significantly attenuated the effect of 5-HT1A on NMDAR currents and microtubule depolymerization. The counteractive effect of 5-HT2A/C on 5-HT1A regulation of synaptic NMDAR response was also observed in PFC pyramidal neurons from intact animals treated with various 5-HT-related drugs. Moreover, 5-HT2A/C stimulation triggered the activation of extracellular signal-regulated kinase (ERK) in dendritic processes. Inhibition of the beta-arrestin/Src/dynamin signaling blocked 5-HT2A/C activation of ERK and the counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR currents. Immunocytochemical studies showed that 5-HT2A/C treatment blocked the inhibitory effect of 5-HT1A on surface NR2B clusters on dendrites, which was prevented by cellular knockdown of beta-arrestins. Taken together, our study suggests that serotonin, via 5-HT1A and 5-HT2A/C receptor activation, regulates NMDAR functions in PFC neurons in a counteractive manner. 5-HT2A/C, by activating ERK via the beta-arrestin-dependent pathway, opposes the 5-HT1A disruption of microtubule stability and NMDAR transport. These findings provide a framework for understanding the complex interactions between serotonin and NMDARs in PFC, which could be important for cognitive and emotional control in which both systems are highly involved.
###end p 4
###begin p 5
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 5
###begin p 6
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 93 86 93 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">MH63128</grant-num>
###xml 98 105 98 105 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">NS48911</grant-num>
###xml 141 203 141 203 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Alliance for Research on Schizophrenia and Depression</grant-sponsor>
###xml 213 237 213 237 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Independent Investigator</grant-sponsor>
###xml 261 286 261 286 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">NARSAD Young Investigator</grant-sponsor>
###xml 446 459 446 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported, in whole or in part, by National Institutes of Health Grants MH63128 and NS48911. This work was also supported by a National Alliance for Research on Schizophrenia and Depression (NARSAD) Independent Investigator Award (to Z. Y.) and a NARSAD Young Investigator Award (to E. Y.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 6
###begin p 7
###xml 16 17 16 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">2</xref>
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 246 247 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 592 594 592 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 603 605 603 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 685 686 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 771 773 771 773 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 908 910 908 910 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 996 997 996 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 1073 1075 1073 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1102 1104 1102 1104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1159 1161 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 1163 1165 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 1202 1204 1202 1204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1213 1215 1213 1215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 266 270 <span type="species:ncbi:10090">Mice</span>
###xml 1149 1157 <span type="species:ncbi:9606">patients</span>
Serotonin (5-HT)2 is a key neuromodulator mediating diverse cognitive and emotional functions in the central nervous system (1). The pleiotropic functions of serotonin are afforded by the concerted actions of multiple 5-HT receptor subtypes, 5-HT1- to 5-HT7 (2, 3). Mice lacking 5-HT receptors exhibit phenotypes ranging from increased anxiety (4), to elevated aggression (5), to antidepressant-like behaviors (6). One of the major targets of serotonin is prefrontal cortex (PFC), a crucial brain region controlling emotion and cognition (7, 8). Several lines of evidence have shown that 5-HT1A and 5-HT2A receptors, which are abundantly co-expressed in most of PFC pyramidal neurons (9), often have opposing actions on common substrates. For instance, activation of 5-HT1A receptors results in neuronal inhibition by increasing potassium currents (10) and decreasing calcium currents (11). In contrast, 5-HT2A receptor stimulation leads to neuronal excitation by suppressing potassium currents (2) and enhancing pre-synaptic glutamate release (12). Moreover, elevated 5-HT1A receptors and reduced 5-HT2A receptors are found in PFC of schizophrenia patients (13, 14), suggesting that the levels of 5-HT1A and 5-HT2A receptors are differentially altered in diseased states.
###end p 7
###begin p 8
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 669 671 669 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 778 780 778 780 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 827 829 827 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
###xml 598 603 <span type="species:ncbi:10090">mouse</span>
One of the potential cellular targets of 5-HT receptors involved in cognitive and emotional control is the NMDA-type glutamate receptor, a ligand-gated ion channel that has been implicated in the pathophysiology of mental disorders (15). NMDAR hypofunction caused by systemic administration of non-competitive NMDAR antagonists or knockdown of NMDAR expression produces schizophrenia-like behavioral symptoms (16-18). Moreover, it has been found that the expression of NMDARs is reduced in postmortem brains of depressed patients (19), and chronic antidepressant treatment enhances NMDAR levels in mouse brains (20). Our previous study has shown that activation of 5-HT1A receptors suppresses NMDAR channel function in PFC pyramidal neurons (21). It remains unknown whether 5-HT2A receptor activation has any impact on the 5-HT1A-NMDAR interaction.
###end p 8
###begin p 9
###xml 36 38 36 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 47 51 47 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 377 379 377 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 388 392 388 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
Here we show that activation of 5-HT1A and 5-HT2A/C receptors in PFC pyramidal neurons regulates NMDAR channels in a counteractive manner by converging on the microtubule-based transport of NMDARs that is regulated by ERK. Given the importance of NMDAR and serotonin in mental processes under normal and pathological conditions, the complex regulation of NMDAR function by 5-HT1A and 5-HT2A/C receptors may provide a molecular and cellular mechanism underlying the role of serotonin in regulating cognitive and emotional behaviors.
###end p 9
###begin title 10
EXPERIMENTAL PROCEDURES
###end title 10
###begin p 11
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Whole Cell Recordings</italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 236 237 236 237 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 265 266 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 284 285 284 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 360 361 360 361 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 406 407 406 407 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 414 415 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 423 424 423 424 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 442 443 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 489 494 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N,N,N</italic>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 541 542 541 542 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 557 558 557 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 599 600 599 600 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1130 1131 1121 1122 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Whole Cell Recordings-Whole cell current recordings of cultured PFC neurons employed standard voltage-clamp techniques as those we described previously (21, 22). The external solution for recording NMDAR-mediated current contained (in mm): 127 NaCl, 20 CsCl, 1 CaCl2, 10 HEPES, 5 BaCl2, 12 glucose, 0.001 tetrodotoxin, and glycine 0.02, pH 7.3-7.4, 300-305 mosm/liter. The internal solution contained (in mm): 180 N-methyl-d-glucamine, 4 MgCl2, 40 HEPES, 0.5 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, 12 phosphocreatine, 3 Na2ATP, and 0.5 Na2GTP, 0.1 leupeptin, pH 7.2-3, 265-270 mosm/liter. Recordings were obtained with an Axon Instruments (Union City, CA) 200B patch clamp amplifier that was monitored by an IBM PC running pClamp 8 with a DigiData 1320 series interface. Electrode resistances were normally 2-4 MOmega in bath solution. Following seal rupture, series resistance (4-10 MOmega) was compensated (70-90%). Attention was applied to monitor the series resistance, and recordings were stopped when a significant increase (>20%) occurred. The whole cell NMDAR-mediated current was evoked by NMDA (100 mum) application for 2 s every 30 s with neurons held at -60 mV. Drugs were applied with a "sewer pipe" system. The array of drug capillaries was positioned a few hundred micrometers from the cell under recording. Solution changes were controlled by the SF-77B fast-step solution stimulus delivery device (Warner Instruments, Hamden, CT). Data were analyzed with AxoGraph (Axon instruments) and KaleidaGraph (Albeck Software). ANOVA was performed to compare the differential degrees of current regulation between experimental groups subjected to different drug treatment. Data are expressed as the mean +/- S.E.
###end p 11
###begin p 12
###xml 0 41 0 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Electrophysiological Recordings in Slices</italic>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 273 274 269 270 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 329 330 325 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 397 398 393 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 441 442 437 438 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 581 582 570 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 588 589 577 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 644 645 632 633 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 669 670 656 657 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 765 766 748 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 1679 1681 1641 1643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Electrophysiological Recordings in Slices-To record NMDAR-mediated synaptic transmission, we performed the standard whole cell recording techniques in layer V PFC pyramidal neurons (21, 23). Patch pipettes (5-9 MOmega) were filled with the following internal solution (in mm): 130 cesium methanesulfonate, 10 CsCl, 4 NaCl, 1 MgCl2, 10 HEPES, 5 EGTA, 2.2 QX-314, 12 phosphocreatine, 5 MgATP, 0.5 Na2GTP, 0.1 leupeptin, pH 7.2-7.3, 265-270 mosm/liter. PFC slices (300 mum) were perfused at room temperature (22-24 degreesC), with artificial cerebrospinal fluid was bubbled with 95% O2/5% CO2 containing 6-cyano-7-nitroquinoxaline-2,3-dione (20 mum) and bicuculline (10 mum) to block alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid/kainite receptors and GABAA receptors, respectively. Neurons were observed with a 40x water-immersion lens and illuminated with near infrared IR light, and the image was captured with an IR-sensitive charge-coupled device camera. All recordings were performed using a Multiclamp 700A amplifier. Upon application of negative pressure, the membrane was tightly sealed with resistance (2-10 GOmega). With additional suction, the membrane was disrupted into the whole cell configuration. The access resistances ranged from 13 to 18 MOmega with 50-70% compensation. Evoked currents were generated with a pulse from a stimulation isolation unit controlled by an S48 pulse generator (Astro-Med). A bipolar stimulating electrode (Fredrick Haer Company) was positioned approximately100mum from the neuron upon recording. Prior to stimulation, neurons (clamped at -70 mV) were depolarized to +60 mV for 3 s to fully eliminate the voltage-dependent Mg2+ block of NMDAR. Age-matched saline controls were done side-by-side with drug-injected animals on each day of experiments. To minimize variations between slices, the stimulus with the same intensity was delivered by the stimulating electrode placed at the same location. Data analyses were performed with the Clampfit software (Axon Instruments).
###end p 12
###begin p 13
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 254 255 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 275 276 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 326 327 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
The agents we used include serotonin, 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT), alpha-Me-5HT, (-)-2,5-dimethoxy-4-iodoamphetamine, ketanserin, benzothiazole, colchicine (Sigma), dynamin inhibitory peptide (Tocris), 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) and 4-amino-7-phenylpyrazol[3,4-d]pyrimidine (PP3) (Calbiochem). They were made up as concentrated stocks in water or DMSO and stored at -20 degreesC. Stocks were thawed and diluted immediately prior to experiments.
###end p 13
###begin p 14
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Animal Treatment</italic>
###xml 28 32 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 154 158 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Animal Treatment-Young male rats (25-28 days old) were administered intraperitoneally with the drugs as described in the text. For stereotaxic injection, rats were anesthetized with pentobarbital sodium (50 mg/kg intraperitoneal) and then mounted into a stereotaxic apparatus (David Kopf Instruments). Fluoxetine (fluox) (2 mul, 0.34 mg/ml, dissolved in saline) were injected unilaterally into the PFC region using a Hamilton syringe (22-gauge needle) at a rate of 0.5 mul/min. The coordinates of the lateral PFC used are 1.0-1.4 mm lateral from midline, 2.2 mm anterior to Bregma, and 3.3 mm dorsal to ventral.
###end p 14
###begin p 15
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Small Interfering RNA</italic>
###xml 184 186 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 452 460 437 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Small Interfering RNA-To knock down the endogenous beta-arrestin expression, we used the small interfering RNA (siRNA) that specifically targets beta-arrestin1 or beta-arrestin2 mRNA (24). The siRNA oligonucleotide sequences were: 5'-GGCGAGUCUACGUGACACUtt-3' (for beta-arrestin1) and 5'-GGACCGGAASGUGUUUGUGtt-3' (for beta-arrestin2). The siRNA (purchased from Ambion, Austin, TX) was co-transfected with enhanced GFP into cultured PFC neurons (11 days in vitro) using the Lipofectamine 2000 method. Biochemical, immunocytochemical, or electrophysiological experiments were performed in neurons after 2-3 days of transfection.
###end p 15
###begin p 16
###xml 0 27 0 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Measurement of Free Tubulin</italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 131 132 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 152 160 152 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 272 273 266 267 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 292 293 286 287 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 298 299 292 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 304 305 298 299 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 317 318 311 312 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 331 332 325 326 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 451 452 438 439 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 471 472 458 459 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 477 478 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 483 484 470 471 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 496 497 483 484 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 506 507 493 494 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Measurement of Free Tubulin-Free tubulin from PFC cultures was extracted as described previously (21). Cultured PFC neurons (2 x 105 cells/cm2, 14 days in vitro) in 3.5-cm dishes were washed twice at 37 degreesC with 1 ml of microtubule stabilizing buffer containing (0.1 m MES (pH 6.75), 1 mm MgSO4, 2 mm EGTA, 0.1 mm EDTA, and 4 m glycerol). Cultures were then incubated at 37 degreesC for 5 min in 600 mul of soluble tubulin extraction buffer (0.1 m MES (pH 6.75), 1 mm MgSO4, 2 mm EGTA, 0.1 mm EDTA, 4 m glycerol, and 0.1% Triton X-100) with the addition of protease inhibitor mixture tablets (Roche Applied Science). The soluble extract was centrifuged at 37 degreesC for 2 min, and the supernatant was collected. Equal amounts of total protein were analyzed by Western blotting using anti-alpha-tubulin (Sigma). The intensity of tubulin bands was quantitatively analyzed with Image (National Institutes of Health).
###end p 16
###begin p 17
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 27 31 27 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 62 64 62 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 9 155 9 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors counteracts the 5-HT<sub>1A</sub> -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons.</bold>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 266 268 266 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 283 284 282 283 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 351 355 346 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 370 371 364 365 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 386 387 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 466 467 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 472 473 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 546 547 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 551 552 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 584 594 576 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 609 610 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 629 630 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 633 634 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 698 699 689 690 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 739 740 725 726 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 762 766 748 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 784 785 769 770 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 788 789 773 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 967 968 950 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 984 9 967 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><bold>Activation of 5-HT<sub>2A/C</sub> receptors counteracts the 5-HT<sub>1A</sub> -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons.</bold><italic>A</italic> and <italic>C</italic>, plot of normalized peak NMDAR currents (<italic>A</italic>) or NMDAR-EPSC (<italic>C</italic>) as a function of time and 8-OH-DPAT (5-HT<sub>1A</sub> agonist, 20 &#956;<sc>m</sc>) application in neurons treated with or without &#945;-Me-5HT (5-HT<sub>2A/C</sub> agonist, 20 &#956;<sc>m</sc>). Each point (<italic>C</italic>) represents the average peak (mean &#177; S.E.) of three consecutive NMDAR-EPSC. <italic>B</italic> and <italic>D</italic>, representative current traces taken from the records used to construct <italic>A</italic> or <italic>C</italic> (at time points denoted by #). <italic>Scale bars</italic>: 100 pA, 1 s (<italic>B</italic>); 100 pA, 100 ms (<italic>D</italic>). <italic>E</italic>, plot of peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) and ketanserin (5-HT<sub>2A/C</sub> antagonist, 20 &#956;<sc>m</sc>). <italic>F</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the presence or absence of various 5-HT receptor agonists or antagonists. *, <italic>p</italic> &lt; 0.001, ANOVA.</p>
###xml 9 984 9 967 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><bold>Activation of 5-HT<sub>2A/C</sub> receptors counteracts the 5-HT<sub>1A</sub> -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons.</bold><italic>A</italic> and <italic>C</italic>, plot of normalized peak NMDAR currents (<italic>A</italic>) or NMDAR-EPSC (<italic>C</italic>) as a function of time and 8-OH-DPAT (5-HT<sub>1A</sub> agonist, 20 &#956;<sc>m</sc>) application in neurons treated with or without &#945;-Me-5HT (5-HT<sub>2A/C</sub> agonist, 20 &#956;<sc>m</sc>). Each point (<italic>C</italic>) represents the average peak (mean &#177; S.E.) of three consecutive NMDAR-EPSC. <italic>B</italic> and <italic>D</italic>, representative current traces taken from the records used to construct <italic>A</italic> or <italic>C</italic> (at time points denoted by #). <italic>Scale bars</italic>: 100 pA, 1 s (<italic>B</italic>); 100 pA, 100 ms (<italic>D</italic>). <italic>E</italic>, plot of peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) and ketanserin (5-HT<sub>2A/C</sub> antagonist, 20 &#956;<sc>m</sc>). <italic>F</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the presence or absence of various 5-HT receptor agonists or antagonists. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption>
###xml 984 984 967 967 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690001"/>
###xml 0 984 0 967 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="18"><bold>Activation of 5-HT<sub>2A/C</sub> receptors counteracts the 5-HT<sub>1A</sub> -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons.</bold><italic>A</italic> and <italic>C</italic>, plot of normalized peak NMDAR currents (<italic>A</italic>) or NMDAR-EPSC (<italic>C</italic>) as a function of time and 8-OH-DPAT (5-HT<sub>1A</sub> agonist, 20 &#956;<sc>m</sc>) application in neurons treated with or without &#945;-Me-5HT (5-HT<sub>2A/C</sub> agonist, 20 &#956;<sc>m</sc>). Each point (<italic>C</italic>) represents the average peak (mean &#177; S.E.) of three consecutive NMDAR-EPSC. <italic>B</italic> and <italic>D</italic>, representative current traces taken from the records used to construct <italic>A</italic> or <italic>C</italic> (at time points denoted by #). <italic>Scale bars</italic>: 100 pA, 1 s (<italic>B</italic>); 100 pA, 100 ms (<italic>D</italic>). <italic>E</italic>, plot of peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) and ketanserin (5-HT<sub>2A/C</sub> antagonist, 20 &#956;<sc>m</sc>). <italic>F</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the presence or absence of various 5-HT receptor agonists or antagonists. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption><graphic xlink:href="zbc0290841690001"/></fig>
FIGURE 1.Activation of 5-HT2A/C receptors counteracts the 5-HT1A -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons.A and C, plot of normalized peak NMDAR currents (A) or NMDAR-EPSC (C) as a function of time and 8-OH-DPAT (5-HT1A agonist, 20 mum) application in neurons treated with or without alpha-Me-5HT (5-HT2A/C agonist, 20 mum). Each point (C) represents the average peak (mean +/- S.E.) of three consecutive NMDAR-EPSC. B and D, representative current traces taken from the records used to construct A or C (at time points denoted by #). Scale bars: 100 pA, 1 s (B); 100 pA, 100 ms (D). E, plot of peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 mum) in the presence of alpha-Me-5HT (20 mum) and ketanserin (5-HT2A/C antagonist, 20 mum). F, cumulative data (mean +/- S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the presence or absence of various 5-HT receptor agonists or antagonists. *, p < 0.001, ANOVA.
###end p 17
###begin p 18
###xml 18 22 18 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 146 0 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors counteracts the 5-HT<sub>1A</sub> -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons.</bold>
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 257 259 257 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 274 275 273 274 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 342 346 337 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 361 362 355 356 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 377 378 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 457 458 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 463 464 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 537 538 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 542 543 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 575 585 567 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 600 601 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 620 621 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 624 625 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 689 690 680 681 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 730 731 716 717 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 753 757 739 743 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 775 776 760 761 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 779 780 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 958 959 941 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Activation of 5-HT2A/C receptors counteracts the 5-HT1A -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons.A and C, plot of normalized peak NMDAR currents (A) or NMDAR-EPSC (C) as a function of time and 8-OH-DPAT (5-HT1A agonist, 20 mum) application in neurons treated with or without alpha-Me-5HT (5-HT2A/C agonist, 20 mum). Each point (C) represents the average peak (mean +/- S.E.) of three consecutive NMDAR-EPSC. B and D, representative current traces taken from the records used to construct A or C (at time points denoted by #). Scale bars: 100 pA, 1 s (B); 100 pA, 100 ms (D). E, plot of peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 mum) in the presence of alpha-Me-5HT (20 mum) and ketanserin (5-HT2A/C antagonist, 20 mum). F, cumulative data (mean +/- S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the presence or absence of various 5-HT receptor agonists or antagonists. *, p < 0.001, ANOVA.
###end p 18
###begin p 19
###xml 0 27 0 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunocytochemical Staining</italic>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 319 325 <span type="species:ncbi:9913">bovine</span>
Immunocytochemical Staining-The detection of surface GFP-NR2B (25) was performed as how we described before (21, 22). Briefly, cultured PFC neurons were treated with various agents after transfection, and then fixed in 4% paraformaldehyde for 30 min at room temperature without permeabilization. After incubating in 5% bovine serum albumin to block nonspecific staining, cells were incubated with the anti-GFP antibody (1:100, Chemicon, Temecula, CA) for 1 h at room temperature. After three washes in phosphate-buffered saline, cells were incubated with a rhodamine-conjugated secondary antibody (1: 200, Sigma) for 1 h at room temperature. After washing in phosphate-buffered saline, coverslips were mounted on slides with Vectashield mounting media (Vector Laboratories, Burlingame, CA). Fluorescence images were detected using a 60x objective with a cooled charge-coupled device camera mounted on a Nikon microscope.
###end p 19
###begin p 20
The surface GFP-NR2B clusters were analyzed with ImageJ software. All specimens were imaged under identical conditions and analyzed with identical parameters. A 50-mum segment of dendrite was selected from the equal distance away from the soma of four to six individual neurons. To define dendritic clusters, a single threshold was selected manually. Signal was counted as clusters when its intensity was 2- to 3-fold greater than the overall fluorescence on the dendritic shaft. Three to four independent experiments were performed. Quantitative analyses were performed blindly without knowledge of experimental conditions.
###end p 20
###begin p 21
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical Measurement of Surface Receptors</italic>
###xml 430 431 429 430 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 436 437 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 444 445 443 444 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 455 456 454 455 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 467 468 466 467 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 478 479 477 478 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 505 506 504 505 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 532 533 531 532 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 634 635 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1115 1116 1098 1099 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
Biochemical Measurement of Surface Receptors-After treatment, PFC slices were incubated with artificial cerebrospinal fluid containing 1 mg/ml Sulfo-NHS-LC-Biotin (Pierce) for 20 min on ice. The slices were then rinsed three times in Tris-buffered saline to quench the biotin reaction, followed by homogenization in 300 mul of modified radioimmune precipitation assay buffer (1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 50 mm NaPO4, 150 mm NaCl, 2 mm EDTA, 50 mm NaF, 10 mm sodium pyrophosphate, 1 mm sodium orthovanadate, 1 mm phenylmethylsulfonyl fluoride, and 1 mg/ml leupeptin). The homogenates were centrifuged at 14,000 x g for 15 min at 4 degreesC. 15 mug of homogenates was removed to measure total proteins. For surface protein detection, 150 mug of homogenates was incubated with 100 mul of 50% NeutrAvidin-Agarose (Pierce) for 2 h at 4 degreesC, and bound proteins were resuspended in 25 mul of SDS sample buffer and boiled. Quantitative Western blots were performed on both total and biotinylated (surface) proteins using anti-NR1, anti-NR2B (Upstate Biotechnology, Lake Placid, NY), and anti-GABAAR beta2/3 (Chemicon).
###end p 21
###begin title 22
RESULTS
###end title 22
###begin p 23
###xml 18 20 18 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 29 33 29 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 0 122 0 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>1A</sub> and 5-HT<sub>2A/C</sub> Receptors Regulates NMDAR-mediated Ionic and Synaptic Currents in a Counteractive Manner</italic>
###xml 171 173 171 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 288 290 288 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 299 303 299 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 362 363 362 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 382 384 382 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 457 461 457 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 489 490 484 485 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 531 532 525 526 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 655 656 649 650 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 686 687 679 680 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 710 711 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 716 717 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 702 718 695 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 (<italic>A</italic> and <italic>B</italic>)</xref>
###xml 743 745 736 738 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 770 771 762 763 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 823 824 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 962 963 946 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1038 1039 1017 1018 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1055 1056 1032 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1067 1068 1043 1044 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1084 1085 1058 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1104 1108 1078 1082 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1179 1180 1152 1153 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1196 1197 1167 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1209 1210 1179 1180 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1226 1227 1194 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1302 1304 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 1428 1430 1396 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 1456 1457 1424 1425 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1784 1788 1752 1756 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1862 1864 1830 1832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
Activation of 5-HT1A and 5-HT2A/C Receptors Regulates NMDAR-mediated Ionic and Synaptic Currents in a Counteractive Manner-We have previously found that activation of 5-HT1A receptors reduces NMDAR currents in PFC pyramidal neurons (21). To examine the potential interactions between 5-HT1A and 5-HT2A/C receptors on NMDAR functions, we tested the impact of 5-HT2 activation on 5-HT1A regulation of NMDAR currents by preincubating PFC cultures with the 5-HT2A/C agonist alpha-Me-5HT (20 mum, 10-30 min). Application of NMDA (100 mum) elicited an inward current that was partially desensitized and was completely eliminated by the NMDA receptor antagonist d-aminophosphonovalerate (50 mum). As shown in Fig. 1 (A and B), application of the 5-HT1A agonist 8-OH-DPAT (20 mum) reversibly reduced NMDAR currents (21.3 +/- 0.7%, n = 16). However, in alpha-Me-5HT-treated neurons, the reduction of NMDAR current by 8-OH-DPAT was substantially attenuated (6.4 +/- 0.7%, n = 8). alpha-Me-5HT alone did not significantly affect NMDAR currents (1 mum: 4.0 +/- 0.8%, n = 5; 20 mum: 5.7 +/- 1.4%, n = 7). Another 5-HT2A/C agonist DOI also had no effect on NMDAR currents at low doses (0.05 mum: 4.2 +/- 1.2%, n = 5; 0.1 mum: 4.0 +/- 2.5%, n = 5), which are different from the inhibitory effect of DOI shown before (26). The discrepancy may be due to different experimental procedures in recording NMDA-induced currents. In a previous study (26), microdrops of NMDA (1 mm, every 15 min) were applied to PFC slices, which did not allow the accurate detection of peak NMDA currents because of the slow diffusion of the ligand. Moreover, it was not a pure postsynaptic preparation like dissociated neurons, which could have indirect effects due to changes in the circuit. Our results suggest that 5-HT2A/C activation alone does not directly affect NMDAR currents but opposes 5-HT1A regulation of NMDAR currents in PFC pyramidal neurons.
###end p 23
###begin p 24
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 27 31 27 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 58 60 58 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 9 115 9 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of 5-HT<sub>2A/C</sub> receptors unmasks the 5-HT<sub>1A</sub> -mediated reduction of NMDAR-EPSC in response to 5-HT.</bold>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 240 241 239 240 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 286 290 285 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 314 317 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ket</italic>
###xml 324 325 322 323 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 328 338 326 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 356 357 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 517 518 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 534 9 532 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><bold>Inhibition of 5-HT<sub>2A/C</sub> receptors unmasks the 5-HT<sub>1A</sub> -mediated reduction of NMDAR-EPSC in response to 5-HT.</bold><italic>A</italic>, representative NMDAR-EPSC traces (average of three trials) showing the regulation of NMDAR-EPSC by 5-HT (10, 40, or 100 &#956;<sc>m</sc>) in neurons treated with or without the 5-HT<sub>2A/C</sub> antagonist ketanserin (<italic>ket</italic>, 20 &#956;<sc>m</sc>). <italic>Scale bars</italic>: 100 pA, 100 ms. <italic>B</italic>, dose-response curves summarizing the percentage reduction of NMDAR-EPSC by different concentrations of 5-HT in neurons treated with or without ketanserin. *, <italic>p</italic> &lt; 0.001, ANOVA.</p>
###xml 9 534 9 532 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25"><bold>Inhibition of 5-HT<sub>2A/C</sub> receptors unmasks the 5-HT<sub>1A</sub> -mediated reduction of NMDAR-EPSC in response to 5-HT.</bold><italic>A</italic>, representative NMDAR-EPSC traces (average of three trials) showing the regulation of NMDAR-EPSC by 5-HT (10, 40, or 100 &#956;<sc>m</sc>) in neurons treated with or without the 5-HT<sub>2A/C</sub> antagonist ketanserin (<italic>ket</italic>, 20 &#956;<sc>m</sc>). <italic>Scale bars</italic>: 100 pA, 100 ms. <italic>B</italic>, dose-response curves summarizing the percentage reduction of NMDAR-EPSC by different concentrations of 5-HT in neurons treated with or without ketanserin. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption>
###xml 534 534 532 532 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690002"/>
###xml 0 534 0 532 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="25"><bold>Inhibition of 5-HT<sub>2A/C</sub> receptors unmasks the 5-HT<sub>1A</sub> -mediated reduction of NMDAR-EPSC in response to 5-HT.</bold><italic>A</italic>, representative NMDAR-EPSC traces (average of three trials) showing the regulation of NMDAR-EPSC by 5-HT (10, 40, or 100 &#956;<sc>m</sc>) in neurons treated with or without the 5-HT<sub>2A/C</sub> antagonist ketanserin (<italic>ket</italic>, 20 &#956;<sc>m</sc>). <italic>Scale bars</italic>: 100 pA, 100 ms. <italic>B</italic>, dose-response curves summarizing the percentage reduction of NMDAR-EPSC by different concentrations of 5-HT in neurons treated with or without ketanserin. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption><graphic xlink:href="zbc0290841690002"/></fig>
FIGURE 2.Inhibition of 5-HT2A/C receptors unmasks the 5-HT1A -mediated reduction of NMDAR-EPSC in response to 5-HT.A, representative NMDAR-EPSC traces (average of three trials) showing the regulation of NMDAR-EPSC by 5-HT (10, 40, or 100 mum) in neurons treated with or without the 5-HT2A/C antagonist ketanserin (ket, 20 mum). Scale bars: 100 pA, 100 ms. B, dose-response curves summarizing the percentage reduction of NMDAR-EPSC by different concentrations of 5-HT in neurons treated with or without ketanserin. *, p < 0.001, ANOVA.
###end p 24
###begin p 25
###xml 18 22 18 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of 5-HT<sub>2A/C</sub> receptors unmasks the 5-HT<sub>1A</sub> -mediated reduction of NMDAR-EPSC in response to 5-HT.</bold>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 231 232 230 231 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 277 281 276 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 305 308 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ket</italic>
###xml 315 316 313 314 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 319 329 317 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 347 348 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 508 509 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Inhibition of 5-HT2A/C receptors unmasks the 5-HT1A -mediated reduction of NMDAR-EPSC in response to 5-HT.A, representative NMDAR-EPSC traces (average of three trials) showing the regulation of NMDAR-EPSC by 5-HT (10, 40, or 100 mum) in neurons treated with or without the 5-HT2A/C antagonist ketanserin (ket, 20 mum). Scale bars: 100 pA, 100 ms. B, dose-response curves summarizing the percentage reduction of NMDAR-EPSC by different concentrations of 5-HT in neurons treated with or without ketanserin. *, p < 0.001, ANOVA.
###end p 25
###begin p 26
###xml 39 40 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 59 61 59 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 150 166 150 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 (<italic>C</italic> and <italic>D</italic>)</xref>
###xml 254 255 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 268 269 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 262 269 260 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>F</italic></xref>
###xml 374 375 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 388 389 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 382 389 374 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>F</italic></xref>
###xml 412 416 404 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 530 534 518 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 563 564 550 551 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 585 586 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 579 586 566 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 636 638 619 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 699 700 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 712 713 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 706 713 687 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>F</italic></xref>
###xml 809 810 790 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 839 840 819 820 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 855 856 833 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 868 869 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 862 869 840 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>F</italic></xref>
###xml 905 909 883 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 958 960 936 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
We further tested the influence of 5-HT2 activation on 5-HT1A regulation of NMDAR-EPSC mediated by synaptic NMDA receptors in PFC slices. As shown in Fig. 1 (C and D), application of 8-OH-DPAT potently reduced the amplitude of NMDAR-EPSC (37.1 +/- 2.1%; n = 10 (Fig. 1F)). However, this reduction was significantly attenuated in the presence of alpha-Me-5HT (10.4 +/- 0.7%; n = 13 (Fig. 1F)). To verify that 5-HT2A/C receptors were mediating this regulatory effect of alpha-Me-5HT, we pre-treated PFC slices with the specific 5-HT2A/C antagonist ketanserin (20 mum). As shown in Fig. 1E, alpha-Me-5HT failed to oppose the effect of 5-HT1A on NMDAR-EPSC in the presence of ketanserin (36.8 +/- 7.1%; n = 5 (Fig. 1F)). In contrast, the reduction of NMDAR-EPSC by 8-OH-DPAT was intact in the presence of the 5-HT4 agonist benzothiazole (20 mum, 33 +/- 2.9%; n = 5 (Fig. 1F)). These results indicate that 5-HT2A/C receptor activation selectively counteracts 5-HT1A regulation of NMDAR functions in PFC pyramidal neurons.
###end p 26
###begin p 27
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 60 64 60 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 313 314 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 340 356 340 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 (<italic>A</italic> and <italic>B</italic>)</xref>
###xml 459 460 458 459 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 474 475 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 486 487 482 483 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 504 505 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 517 518 510 511 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 535 536 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 579 583 570 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 612 613 602 603 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 685 686 674 675 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 703 704 690 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 715 716 701 702 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 733 734 717 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 746 747 729 730 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 761 762 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 790 791 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 880 882 861 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
We next examined what would happen when both 5-HT1A and 5-HT2A/C receptors are co-activated by serotonin. If both signals oppose each other, then blocking one receptor activation would unmask the effect of the other. Thus, we tested the effect of serotonin on NMDAR-EPSC in PFC slices treated with or without 5-HT2 antagonists. As shown in Fig. 2 (A and B), different concentrations of serotonin reduced the amplitude of NMDAR-EPSC to different extents (10 mum:21 +/- 2.3%, n = 4; 40 mum: 28.5 +/- 4.9%, n = 4; 100 mum: 29.4 +/- 4.8%, n = 5). However, in the presence of the 5-HT2A/C antagonist ketanserin (20 mum), the reduction of NMDAR-EPSC by serotonin was greatly augmented (10 mum: 35.2 +/- 2.2%, n = 7; 40 mum: 43.0 +/- 2.0%, n = 6; 100 mum:47 +/- 1.9%, n = 7). It suggests that 5-HT2 receptor activation in response to serotonin masks part of the inhibitory action of 5-HT1A receptors on NMDAR channels.
###end p 27
###begin p 28
###xml 72 80 72 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 175 177 175 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 186 190 186 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 365 367 365 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 375 379 375 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 408 409 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 402 409 402 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 516 518 516 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 564 565 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 594 595 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 602 603 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 675 679 671 675 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 719 720 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 848 849 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 903 905 883 885 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 916 923 896 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 979 981 959 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1000 1004 980 984 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1025 1032 1005 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1196 1197 1170 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1226 1227 1198 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1255 1257 1227 1229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
To assess whether the serotonergic regulation of NMDARs, which we found in vitro, is also occurring in vivo, we tested whether endogenous serotonin, via the activation of 5-HT1A and 5-HT2A/C receptors, could regulate NMDAR functions in a similar manner in intact animals. First, we examined NMDAR-EPSC in PFC slices from animals intraperitoneally injected with 5-HT1A or 5-HT2A/C agonists. As shown in Fig. 3A, the amplitude of NMDAR-EPSC was significantly smaller in animals intraperitoneally injected with the 5-HT1A agonist 8-OH-DPAT (saline: 379.8 +/- 8.9 pA, n = 8; DPAT: 166 +/- 11.5 pA, n = 11; p < 0.001, ANOVA), whereas it was largely unaltered by injecting the 5-HT2A/C agonist alpha-Me-5HT (349 +/- 12.2 pA, n = 10). However, the effect of 8-OH-DPAT injection was blocked by injecting alpha-Me-5HT (DPAT + alpha-Me-5HT: 335 +/- 15.9 pA, n = 12). These results indicate that activation of 5-HT1A receptors in vivo down-regulates NMDAR functions, and this effect of 5-HT1A is opposed by 5-HT2A/C receptor activation in vivo. Moreover, the amplitude of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor-EPSC was unchanged by 8-OH-DPAT injection (saline: 113 +/- 11.8 pA, n = 11; DPAT: 112 +/- 9.9 pA, n = 10), suggesting that 5-HT1A activation in PFC is specifically targeting postsynaptic NMDARs rather than presynaptic glutamate release.
###end p 28
###begin p 29
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 121 123 121 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 215 219 215 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 9 228 9 228 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT<sub>1A</sub> agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT<sub>2A/C</sub> agonist.</bold>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 395 396 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 463 464 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 728 738 720 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">short bars</italic>
###xml 740 745 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 858 868 850 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 886 887 878 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 982 983 973 974 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 9 1087 9 1078 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30"><bold>The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT<sub>1A</sub> agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT<sub>2A/C</sub> agonist.</bold><italic>A</italic> and <italic>B</italic>, dot plots showing the peak amplitude of NMDAR-EPSC recorded in PFC pyramidal neurons from animals with a single intraperitoneal injection of different drugs. <italic>A</italic>, saline, 8-OH-DPAT, &#945;-Me-5HT, or 8-OH-DPAT plus &#945;-Me-5HT; <italic>B</italic>, saline, fluoxetine, WAY-100635, WAY-100635 plus fluoxetine, ketanserin, or ketanserin plus fluoxetine. All drugs were at the concentration of 20 mg/kg. Animals were sacrificed for slicing 1 h after drug administration. Mean values of each group are indicated by <italic>short bars</italic>. <italic>Inset</italic>: representative NMDAR-EPSC traces recorded in PFC pyramidal neurons from animals with different drug injection. <italic>Scale bars</italic>: 100 pA, 100 ms. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of bath application of 8-OH-DPAT (40 &#956;<sc>m</sc>) in PFC pyramidal neurons from animals intraperitoneally injected with fluoxetine (20 mg/kg) or saline.</p>
###xml 9 1087 9 1078 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30"><bold>The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT<sub>1A</sub> agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT<sub>2A/C</sub> agonist.</bold><italic>A</italic> and <italic>B</italic>, dot plots showing the peak amplitude of NMDAR-EPSC recorded in PFC pyramidal neurons from animals with a single intraperitoneal injection of different drugs. <italic>A</italic>, saline, 8-OH-DPAT, &#945;-Me-5HT, or 8-OH-DPAT plus &#945;-Me-5HT; <italic>B</italic>, saline, fluoxetine, WAY-100635, WAY-100635 plus fluoxetine, ketanserin, or ketanserin plus fluoxetine. All drugs were at the concentration of 20 mg/kg. Animals were sacrificed for slicing 1 h after drug administration. Mean values of each group are indicated by <italic>short bars</italic>. <italic>Inset</italic>: representative NMDAR-EPSC traces recorded in PFC pyramidal neurons from animals with different drug injection. <italic>Scale bars</italic>: 100 pA, 100 ms. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of bath application of 8-OH-DPAT (40 &#956;<sc>m</sc>) in PFC pyramidal neurons from animals intraperitoneally injected with fluoxetine (20 mg/kg) or saline.</p></caption>
###xml 1087 1087 1078 1078 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690003"/>
###xml 0 1087 0 1078 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="30"><bold>The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT<sub>1A</sub> agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT<sub>2A/C</sub> agonist.</bold><italic>A</italic> and <italic>B</italic>, dot plots showing the peak amplitude of NMDAR-EPSC recorded in PFC pyramidal neurons from animals with a single intraperitoneal injection of different drugs. <italic>A</italic>, saline, 8-OH-DPAT, &#945;-Me-5HT, or 8-OH-DPAT plus &#945;-Me-5HT; <italic>B</italic>, saline, fluoxetine, WAY-100635, WAY-100635 plus fluoxetine, ketanserin, or ketanserin plus fluoxetine. All drugs were at the concentration of 20 mg/kg. Animals were sacrificed for slicing 1 h after drug administration. Mean values of each group are indicated by <italic>short bars</italic>. <italic>Inset</italic>: representative NMDAR-EPSC traces recorded in PFC pyramidal neurons from animals with different drug injection. <italic>Scale bars</italic>: 100 pA, 100 ms. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of bath application of 8-OH-DPAT (40 &#956;<sc>m</sc>) in PFC pyramidal neurons from animals intraperitoneally injected with fluoxetine (20 mg/kg) or saline.</p></caption><graphic xlink:href="zbc0290841690003"/></fig>
FIGURE 3.The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT1A agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT2A/C agonist.A and B, dot plots showing the peak amplitude of NMDAR-EPSC recorded in PFC pyramidal neurons from animals with a single intraperitoneal injection of different drugs. A, saline, 8-OH-DPAT, alpha-Me-5HT, or 8-OH-DPAT plus alpha-Me-5HT; B, saline, fluoxetine, WAY-100635, WAY-100635 plus fluoxetine, ketanserin, or ketanserin plus fluoxetine. All drugs were at the concentration of 20 mg/kg. Animals were sacrificed for slicing 1 h after drug administration. Mean values of each group are indicated by short bars. Inset: representative NMDAR-EPSC traces recorded in PFC pyramidal neurons from animals with different drug injection. Scale bars: 100 pA, 100 ms. C, plot of normalized peak NMDAR-EPSC showing the effect of bath application of 8-OH-DPAT (40 mum) in PFC pyramidal neurons from animals intraperitoneally injected with fluoxetine (20 mg/kg) or saline.
###end p 29
###begin p 30
###xml 112 114 112 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 206 210 206 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 0 219 0 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT<sub>1A</sub> agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT<sub>2A/C</sub> agonist.</bold>
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 225 226 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 386 387 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 454 455 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 719 729 711 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">short bars</italic>
###xml 731 736 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 849 859 841 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 877 878 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 973 974 964 965 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT1A agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT2A/C agonist.A and B, dot plots showing the peak amplitude of NMDAR-EPSC recorded in PFC pyramidal neurons from animals with a single intraperitoneal injection of different drugs. A, saline, 8-OH-DPAT, alpha-Me-5HT, or 8-OH-DPAT plus alpha-Me-5HT; B, saline, fluoxetine, WAY-100635, WAY-100635 plus fluoxetine, ketanserin, or ketanserin plus fluoxetine. All drugs were at the concentration of 20 mg/kg. Animals were sacrificed for slicing 1 h after drug administration. Mean values of each group are indicated by short bars. Inset: representative NMDAR-EPSC traces recorded in PFC pyramidal neurons from animals with different drug injection. Scale bars: 100 pA, 100 ms. C, plot of normalized peak NMDAR-EPSC showing the effect of bath application of 8-OH-DPAT (40 mum) in PFC pyramidal neurons from animals intraperitoneally injected with fluoxetine (20 mg/kg) or saline.
###end p 30
###begin p 31
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 27 31 27 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 9 160 9 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors attenuates the 5-HT<sub>1A</sub> -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC.</bold>
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 275 276 274 275 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 335 336 329 330 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 380 381 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 547 552 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 613 614 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 631 632 623 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 734 735 725 726 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 786 787 772 773 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 790 791 776 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 948 949 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 964 9 944 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><bold>Activation of 5-HT<sub>2A/C</sub> receptors attenuates the 5-HT<sub>1A</sub> -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC.</bold><italic>A</italic>, Western blot analysis of free tubulin in lysates of cultured PFC neurons treated with or without 8-OH-DPAT (40&#956;<sc>m</sc>, 30 min) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, added 10 min before 8-OH-DPAT treatment). <italic>B</italic>, quantification of free tubulin assay. Free tubulin level was normalized to control (&#8211;), based on the intensity of the tubulin band from Western blot analyses. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of microtubule depolymerizer colchicine (30 &#956;<sc>m</sc>) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>). <italic>D</italic>, cumulative data (mean &#177; S.E.) illustrating the percent reduction of NMDAR-EPSC by colchicine in neurons with or without the exposure to &#945;-Me-5HT. *, <italic>p</italic> &lt; 0.05, ANOVA.</p>
###xml 9 964 9 944 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><bold>Activation of 5-HT<sub>2A/C</sub> receptors attenuates the 5-HT<sub>1A</sub> -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC.</bold><italic>A</italic>, Western blot analysis of free tubulin in lysates of cultured PFC neurons treated with or without 8-OH-DPAT (40&#956;<sc>m</sc>, 30 min) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, added 10 min before 8-OH-DPAT treatment). <italic>B</italic>, quantification of free tubulin assay. Free tubulin level was normalized to control (&#8211;), based on the intensity of the tubulin band from Western blot analyses. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of microtubule depolymerizer colchicine (30 &#956;<sc>m</sc>) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>). <italic>D</italic>, cumulative data (mean &#177; S.E.) illustrating the percent reduction of NMDAR-EPSC by colchicine in neurons with or without the exposure to &#945;-Me-5HT. *, <italic>p</italic> &lt; 0.05, ANOVA.</p></caption>
###xml 964 964 944 944 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690004"/>
###xml 0 964 0 944 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="32"><bold>Activation of 5-HT<sub>2A/C</sub> receptors attenuates the 5-HT<sub>1A</sub> -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC.</bold><italic>A</italic>, Western blot analysis of free tubulin in lysates of cultured PFC neurons treated with or without 8-OH-DPAT (40&#956;<sc>m</sc>, 30 min) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, added 10 min before 8-OH-DPAT treatment). <italic>B</italic>, quantification of free tubulin assay. Free tubulin level was normalized to control (&#8211;), based on the intensity of the tubulin band from Western blot analyses. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of microtubule depolymerizer colchicine (30 &#956;<sc>m</sc>) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>). <italic>D</italic>, cumulative data (mean &#177; S.E.) illustrating the percent reduction of NMDAR-EPSC by colchicine in neurons with or without the exposure to &#945;-Me-5HT. *, <italic>p</italic> &lt; 0.05, ANOVA.</p></caption><graphic xlink:href="zbc0290841690004"/></fig>
FIGURE 4.Activation of 5-HT2A/C receptors attenuates the 5-HT1A -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC.A, Western blot analysis of free tubulin in lysates of cultured PFC neurons treated with or without 8-OH-DPAT (40mum, 30 min) in the absence or presence of alpha-Me-5HT (20 mum, added 10 min before 8-OH-DPAT treatment). B, quantification of free tubulin assay. Free tubulin level was normalized to control (-), based on the intensity of the tubulin band from Western blot analyses. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of microtubule depolymerizer colchicine (30 mum) in the absence or presence of alpha-Me-5HT (20 mum). D, cumulative data (mean +/- S.E.) illustrating the percent reduction of NMDAR-EPSC by colchicine in neurons with or without the exposure to alpha-Me-5HT. *, p < 0.05, ANOVA.
###end p 31
###begin p 32
###xml 18 22 18 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 151 0 151 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors attenuates the 5-HT<sub>1A</sub> -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC.</bold>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 266 267 265 266 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 326 327 320 321 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 371 372 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 538 543 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 604 605 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 622 623 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 725 726 716 717 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 777 778 763 764 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 781 782 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 939 940 919 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Activation of 5-HT2A/C receptors attenuates the 5-HT1A -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC.A, Western blot analysis of free tubulin in lysates of cultured PFC neurons treated with or without 8-OH-DPAT (40mum, 30 min) in the absence or presence of alpha-Me-5HT (20 mum, added 10 min before 8-OH-DPAT treatment). B, quantification of free tubulin assay. Free tubulin level was normalized to control (-), based on the intensity of the tubulin band from Western blot analyses. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of microtubule depolymerizer colchicine (30 mum) in the absence or presence of alpha-Me-5HT (20 mum). D, cumulative data (mean +/- S.E.) illustrating the percent reduction of NMDAR-EPSC by colchicine in neurons with or without the exposure to alpha-Me-5HT. *, p < 0.05, ANOVA.
###end p 32
###begin p 33
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 203 210 203 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 356 357 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 390 391 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 398 399 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 476 478 472 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 524 525 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 562 563 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 603 605 595 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 712 716 704 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 762 763 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 800 801 788 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 808 809 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 869 873 857 861 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 881 883 869 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 983 984 970 971 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1090 1091 1077 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1084 1091 1071 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1116 1117 1101 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1145 1146 1128 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1200 1207 1183 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1230 1238 1213 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1434 1435 1415 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1465 1466 1444 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Next, we examined NMDAR-EPSC in PFC slices from animals intraperitoneally injected with the serotonin re-uptake inhibitor fluoxetine (20 mg/kg) to elevate endogenous 5-HT levels at synapses. As shown in Fig. 3B, the amplitude of NMDAR-EPSC in fluoxetine-injected animals was significantly smaller, compared with saline controls (saline: 403.5 +/- 15.8 pA, n = 11; fluox: 195.1 +/- 12.4 pA, n = 14; p < 0.001, ANOVA). This effect of fluoxetine was blocked by injecting the 5-HT1A antagonist WAY-100635 (WAY: 367 +/- 12.9 pA, n = 12; WAY + fluox: 390 +/- 15.8 pA, n = 12), suggesting the mediation by 5-HT1A receptors. Moreover, the reducing effect of fluoxetine on NMDAR-EPSC was potentiated by injecting the 5-HT2A/C antagonist ketanserin (ket: 392 +/- 12.3 pA, n = 11; ket + fluox: 59.6 +/- 5.2 pA, n = 12; p < 0.001, ANOVA), revealing the counteracting effect of 5-HT2A/C on 5-HT1A regulation of synaptic NMDA responses. Moreover, the effect of bath application of 8-OH-DPAT (40 mum) on NMDAR-EPSC was occluded in animals injected with fluoxetine, as compared with saline controls (Fig. 3C, saline: 40.2 +/- 1.9%, n = 5, fluox: 10.5 +/- 2.5%, n = 6), confirming the common mechanism underlying the in vivo fluoxetine effect and in vitro 8-OH-DPAT effect on NMDARs. In contrast to the strong effect in PFC pyramidal neurons, fluoxetine injection failed to affect NMDAR-EPSC in striatal medium spiny neurons (saline: 375 +/- 15.9 pA, n = 8; fluox: 351 +/- 13.9 pA, n = 10), suggesting the specificity of serotonergic regulation of NMDARs in PFC.
###end p 33
###begin p 34
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 27 31 27 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 9 138 9 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons.</bold>
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 223 224 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 283 286 283 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 347 348 342 343 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 377 378 371 372 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 9 387 9 381 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><bold>Activation of 5-HT<sub>2A/C</sub> receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons.</bold><italic>A</italic> and <italic>B</italic>, immunocytochemical images of cultured PFC neurons stained with phospho-ERK (<italic>A</italic>, <italic>green</italic>) or ERK (<italic>B</italic>, <italic>green</italic>) plus the nucleus marker TOPRO3 (<italic>red</italic>) in the absence (vehicle) or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) or glutamate (100 &#956;<sc>m</sc>, 3 min).</p>
###xml 9 387 9 381 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35"><bold>Activation of 5-HT<sub>2A/C</sub> receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons.</bold><italic>A</italic> and <italic>B</italic>, immunocytochemical images of cultured PFC neurons stained with phospho-ERK (<italic>A</italic>, <italic>green</italic>) or ERK (<italic>B</italic>, <italic>green</italic>) plus the nucleus marker TOPRO3 (<italic>red</italic>) in the absence (vehicle) or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) or glutamate (100 &#956;<sc>m</sc>, 3 min).</p></caption>
###xml 387 387 381 381 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690005"/>
###xml 0 387 0 381 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="35"><bold>Activation of 5-HT<sub>2A/C</sub> receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons.</bold><italic>A</italic> and <italic>B</italic>, immunocytochemical images of cultured PFC neurons stained with phospho-ERK (<italic>A</italic>, <italic>green</italic>) or ERK (<italic>B</italic>, <italic>green</italic>) plus the nucleus marker TOPRO3 (<italic>red</italic>) in the absence (vehicle) or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) or glutamate (100 &#956;<sc>m</sc>, 3 min).</p></caption><graphic xlink:href="zbc0290841690005"/></fig>
FIGURE 5.Activation of 5-HT2A/C receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons.A and B, immunocytochemical images of cultured PFC neurons stained with phospho-ERK (A, green) or ERK (B, green) plus the nucleus marker TOPRO3 (red) in the absence (vehicle) or presence of alpha-Me-5HT (20 mum, 3 min) or glutamate (100 mum, 3 min).
###end p 34
###begin p 35
###xml 18 22 18 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 0 129 0 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons.</bold>
###xml 129 130 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 338 339 333 334 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 368 369 362 363 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Activation of 5-HT2A/C receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons.A and B, immunocytochemical images of cultured PFC neurons stained with phospho-ERK (A, green) or ERK (B, green) plus the nucleus marker TOPRO3 (red) in the absence (vehicle) or presence of alpha-Me-5HT (20 mum, 3 min) or glutamate (100 mum, 3 min).
###end p 35
###begin p 36
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 41 45 41 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 9 131 9 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function is dependent on the &#946;-arrestin/ERK pathway.</bold>
###xml 131 132 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 134 137 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 352 357 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 420 421 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 438 439 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 441 444 427 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 524 525 505 506 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 603 609 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bottom</italic>
###xml 674 679 652 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 740 741 716 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 758 759 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 830 831 805 806 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 882 883 852 853 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 970 971 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1146 1147 1107 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 1163 9 1124 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><bold>The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function is dependent on the &#946;-arrestin/ERK pathway.</bold><italic>A</italic>, <italic>top</italic>: Western blots of &#946;-arrestin 1/2 in PFC cultures transfected without or with siRNA against &#946;-arrestin 1/2 or a scrambled siRNA. Quantification of &#946;-arrestin 1/2 expression under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of three independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>B</italic>, <italic>top</italic>: Western blots of phospho-ERK in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in PFC cultures transfected with or without &#946;-arrestin 1/2 siRNA. <italic>Bottom</italic>: quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of peak NMDAR currents as a function of time and 8-OH-DPAT (20&#956;<sc>m</sc>) application in the presence of&#945;-Me-5HT (20 &#956;<sc>m</sc>) in GFP-positive neurons transfected with or without siRNA against &#946;-arrestin 1/2. <italic>D</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR currents by 8-OH-DPAT in the absence or presence of&#945;-Me-5HT under different conditions. *, <italic>p</italic> &lt; 0.001, ANOVA.</p>
###xml 9 1163 9 1124 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37"><bold>The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function is dependent on the &#946;-arrestin/ERK pathway.</bold><italic>A</italic>, <italic>top</italic>: Western blots of &#946;-arrestin 1/2 in PFC cultures transfected without or with siRNA against &#946;-arrestin 1/2 or a scrambled siRNA. Quantification of &#946;-arrestin 1/2 expression under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of three independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>B</italic>, <italic>top</italic>: Western blots of phospho-ERK in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in PFC cultures transfected with or without &#946;-arrestin 1/2 siRNA. <italic>Bottom</italic>: quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of peak NMDAR currents as a function of time and 8-OH-DPAT (20&#956;<sc>m</sc>) application in the presence of&#945;-Me-5HT (20 &#956;<sc>m</sc>) in GFP-positive neurons transfected with or without siRNA against &#946;-arrestin 1/2. <italic>D</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR currents by 8-OH-DPAT in the absence or presence of&#945;-Me-5HT under different conditions. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption>
###xml 1163 1163 1124 1124 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690006"/>
###xml 0 1163 0 1124 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="37"><bold>The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function is dependent on the &#946;-arrestin/ERK pathway.</bold><italic>A</italic>, <italic>top</italic>: Western blots of &#946;-arrestin 1/2 in PFC cultures transfected without or with siRNA against &#946;-arrestin 1/2 or a scrambled siRNA. Quantification of &#946;-arrestin 1/2 expression under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of three independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>B</italic>, <italic>top</italic>: Western blots of phospho-ERK in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in PFC cultures transfected with or without &#946;-arrestin 1/2 siRNA. <italic>Bottom</italic>: quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of peak NMDAR currents as a function of time and 8-OH-DPAT (20&#956;<sc>m</sc>) application in the presence of&#945;-Me-5HT (20 &#956;<sc>m</sc>) in GFP-positive neurons transfected with or without siRNA against &#946;-arrestin 1/2. <italic>D</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR currents by 8-OH-DPAT in the absence or presence of&#945;-Me-5HT under different conditions. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption><graphic xlink:href="zbc0290841690006"/></fig>
FIGURE 6.The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function is dependent on the beta-arrestin/ERK pathway.A, top: Western blots of beta-arrestin 1/2 in PFC cultures transfected without or with siRNA against beta-arrestin 1/2 or a scrambled siRNA. Quantification of beta-arrestin 1/2 expression under different conditions. Each point represents mean +/- S.E. of three independent experiments. *, p < 0.001, ANOVA. B, top: Western blots of phospho-ERK in the absence or presence of alpha-Me-5HT (20 mum, 3 min) in PFC cultures transfected with or without beta-arrestin 1/2 siRNA. Bottom: quantification of phospho-ERK under different conditions. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of peak NMDAR currents as a function of time and 8-OH-DPAT (20mum) application in the presence ofalpha-Me-5HT (20 mum) in GFP-positive neurons transfected with or without siRNA against beta-arrestin 1/2. D, cumulative data (mean +/- S.E.) summarizing the percentage reduction of NMDAR currents by 8-OH-DPAT in the absence or presence ofalpha-Me-5HT under different conditions. *, p < 0.001, ANOVA.
###end p 36
###begin p 37
###xml 32 36 32 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 122 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function is dependent on the &#946;-arrestin/ERK pathway.</bold>
###xml 122 123 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 125 128 122 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 343 348 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 411 412 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 429 430 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 432 435 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 515 516 496 497 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 594 600 572 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bottom</italic>
###xml 665 670 643 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 731 732 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 749 750 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 821 822 796 797 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 873 874 843 844 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 961 962 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1137 1138 1098 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function is dependent on the beta-arrestin/ERK pathway.A, top: Western blots of beta-arrestin 1/2 in PFC cultures transfected without or with siRNA against beta-arrestin 1/2 or a scrambled siRNA. Quantification of beta-arrestin 1/2 expression under different conditions. Each point represents mean +/- S.E. of three independent experiments. *, p < 0.001, ANOVA. B, top: Western blots of phospho-ERK in the absence or presence of alpha-Me-5HT (20 mum, 3 min) in PFC cultures transfected with or without beta-arrestin 1/2 siRNA. Bottom: quantification of phospho-ERK under different conditions. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of peak NMDAR currents as a function of time and 8-OH-DPAT (20mum) application in the presence ofalpha-Me-5HT (20 mum) in GFP-positive neurons transfected with or without siRNA against beta-arrestin 1/2. D, cumulative data (mean +/- S.E.) summarizing the percentage reduction of NMDAR currents by 8-OH-DPAT in the absence or presence ofalpha-Me-5HT under different conditions. *, p < 0.001, ANOVA.
###end p 37
###begin p 38
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 394 395 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 426 427 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 434 435 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
To further test the effect of 5-HT on NMDARs in PFC networks in vivo without affecting other circuits, we also performed stereotaxic injection of fluoxetine to PFC to elevate the local 5-HT levels. We found that the amplitude of NMDAR-EPSC in PFC pyramidal neurons localized at the proximity of injection sites was significantly smaller, compared with saline controls (saline: 401 +/- 10.1 pA, n = 11; fluox: 162 +/- 13.2 pA, n = 11, p < 0.001, ANOVA).
###end p 38
###begin p 39
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 55 0 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The Opposing Regulation of NMDA Receptors by 5-HT<sub>1A</sub> and</italic>
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 55 103 55 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5-HT<sub>2</sub> Receptors Depends on Microtubule Stability</italic>
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 204 206 204 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 276 278 276 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 438 440 438 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 450 452 450 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 653 654 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 659 660 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 645 661 641 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 (<italic>A</italic> and <italic>B</italic>)</xref>
###xml 694 695 689 690 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 774 775 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 781 782 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 869 870 857 858 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 899 900 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 927 928 913 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 993 995 979 981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
The Opposing Regulation of NMDA Receptors by 5-HT1A and5-HT2 Receptors Depends on Microtubule Stability-Next, we investigated the potential mechanism by which 5-HT2 receptors counteract the effect of 5-HT1A on NMDAR currents in PFC neurons. Previously, we have found that 5-HT1A disrupts NMDA receptor trafficking by destabilizing microtubule integrity (21). Thus, we examined whether microtubule dynamics is the convergent target of 5-HT1A- and 5-HT2A-mediated signaling. To test this, we compared the level of free (depolymerized) tubulin in PFC cultures subjected to 8-OH-DPAT treatment in the absence or presence of alpha-Me5HT. As shown in Fig. 4 (A and B), application of 8-OH-DPAT (40 mum, 20 min) caused a potent increase in free tubulin (1.7 +/- 0.3-fold increase, n = 3, p < 0.001, ANOVA), however, this effect was significantly blocked by alpha-Me-5HT (20 mum, 0.6 +/- 0.2-fold increase, n = 3), indicating that 5-HT2 activation could increase microtubule stability and prevent 5-HT1A-induced microtubule depolymerization.
###end p 39
###begin p 40
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 64 66 64 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 161 163 161 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 197 213 197 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 (<italic>C</italic> and <italic>D</italic>)</xref>
###xml 283 284 282 283 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 346 347 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 367 369 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 404 406 401 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 415 417 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 527 528 519 520 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 546 547 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 599 601 589 591 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 610 611 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
We then tested whether the counteractive effect of 5-HT2 on 5-HT1A regulation of NMDAR currents is due to the opposing regulation of microtubule dynamics by 5-HT1A and 5-HT2 receptors. As shown in Fig. 4 (C and D), bath application of the microtubule depolymerizer, colchicine (30 mum), gradually reduced NMDAR-EPSC in PFC slices (38.0 +/- 2.9%, n = 5, also see Ref. 22), mimicking and occluding the 5-HT1A effect (21). However, this inhibitory effect of colchicine was largely attenuated in the presence of alpha-Me-5HT (20 mum, 11.2 +/- 13.4%, n = 6). These results suggest that activation of 5-HT1A and 5-HT2 receptors could regulate NMDAR currents in a counteractive manner by converging on microtubule dynamics.
###end p 40
###begin p 41
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 74 0 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2</sub> Receptors Induces ERK Activation in Neuronal Processes</italic>
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 275 277 275 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 403 404 403 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 589 593 589 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 871 872 871 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 865 872 865 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 908 909 903 904 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 938 939 932 933 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1161 1162 1151 1152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1308 1309 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1302 1309 1292 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 1340 1341 1330 1331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1426 1428 1416 1418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
Activation of 5-HT2 Receptors Induces ERK Activation in Neuronal Processes-How could 5-HT2 activation increase microtubule stability? Evidence has shown that activation of ERK stabilizes microtubule integrity (27, 28). Moreover, our previous findings have suggested that 5-HT1A reduces ERK activity, which in turn reduces MAP2 phosphorylation and microtubule stability (21). Thus, we speculate that 5-HT2 receptors might activate ERK, leading to increased phosphorylation of MAP2 and its association with microtubules. To test this, we measured the activation of ERK1/2 in response to 5-HT2A/C agonists with an antibody that recognizes activated EKR1/2, which are doubly phosphorylated at Thr-202/Tyr-204 in the activation loop of the kinases (29). As a positive control, we also treated neurons with glutamate, which was reported to activate ERK (30). As shown in Fig. 5A, application of alpha-Me-5HT (20 mum, 3 min) or glutamate (100 mum, 3 min) increased ERK phosphorylation, as compared with vehicle-treated neurons. Unlike glutamate treatment, the alpha-Me-5HT-activated ERK did not co-localize with TOPRO3 (a nucleus marker) staining, suggesting that 5-HT2-activated ERK is mainly targeted to the cytoplasm rather than nucleus. Among all experimental groups, total ERK levels remained unchanged (Fig. 5B). These data suggest that 5-HT2 receptors induce ERK activation, which may oppose the down-regulation of ERK by 5-HT1A receptors.
###end p 41
###begin p 42
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 41 45 41 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 9 132 9 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis.</bold>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 237 238 232 233 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 367 368 361 362 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 423 424 416 417 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 660 661 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 726 731 715 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 792 793 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 810 811 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 886 887 872 873 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 927 928 908 909 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 990 991 970 971 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1030 1031 1009 1010 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1034 1039 1013 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 1112 1122 1091 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 1139 1140 1118 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1352 1353 1325 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 1369 9 1342 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43"><bold>The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis.</bold><italic>A</italic>, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in the absence or presence of the cell-permeable (myristoylated) or non-permeable dynamin inhibitory peptide (both 50 &#956;<sc>m</sc>), or a cell-permeable scrambled control peptide (50 &#956;<sc>m</sc>). This scrambled peptide was fused with the protein transduction domain of the human immunodeficiency virus TAT protein (YGRKKRRQRRR, 53), which rendered it cell-permeable. All peptides were added 30 min before &#945;-Me-5HT treatment. <italic>B</italic>, quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) in cells dialyzed with the dynamin inhibitory peptide (50 &#956;<sc>m</sc>) or a scrambled control peptide (50 &#956;<sc>m</sc>). <italic>Inset</italic>, representative traces of NMDAR-EPSC taken at time points denoted by #. <italic>Scale bars</italic>: 100 pA, 10 ms. <italic>D</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of &#945;-Me-5HT in neurons injected with or without the dynamin inhibitory peptide. *, <italic>p</italic> &lt; 0.001, ANOVA.</p>
###xml 9 1369 9 1342 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43"><bold>The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis.</bold><italic>A</italic>, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in the absence or presence of the cell-permeable (myristoylated) or non-permeable dynamin inhibitory peptide (both 50 &#956;<sc>m</sc>), or a cell-permeable scrambled control peptide (50 &#956;<sc>m</sc>). This scrambled peptide was fused with the protein transduction domain of the human immunodeficiency virus TAT protein (YGRKKRRQRRR, 53), which rendered it cell-permeable. All peptides were added 30 min before &#945;-Me-5HT treatment. <italic>B</italic>, quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) in cells dialyzed with the dynamin inhibitory peptide (50 &#956;<sc>m</sc>) or a scrambled control peptide (50 &#956;<sc>m</sc>). <italic>Inset</italic>, representative traces of NMDAR-EPSC taken at time points denoted by #. <italic>Scale bars</italic>: 100 pA, 10 ms. <italic>D</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of &#945;-Me-5HT in neurons injected with or without the dynamin inhibitory peptide. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption>
###xml 1369 1369 1342 1342 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690007"/>
###xml 0 1369 0 1342 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="43"><bold>The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis.</bold><italic>A</italic>, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in the absence or presence of the cell-permeable (myristoylated) or non-permeable dynamin inhibitory peptide (both 50 &#956;<sc>m</sc>), or a cell-permeable scrambled control peptide (50 &#956;<sc>m</sc>). This scrambled peptide was fused with the protein transduction domain of the human immunodeficiency virus TAT protein (YGRKKRRQRRR, 53), which rendered it cell-permeable. All peptides were added 30 min before &#945;-Me-5HT treatment. <italic>B</italic>, quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) in cells dialyzed with the dynamin inhibitory peptide (50 &#956;<sc>m</sc>) or a scrambled control peptide (50 &#956;<sc>m</sc>). <italic>Inset</italic>, representative traces of NMDAR-EPSC taken at time points denoted by #. <italic>Scale bars</italic>: 100 pA, 10 ms. <italic>D</italic>, cumulative data (mean &#177; S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of &#945;-Me-5HT in neurons injected with or without the dynamin inhibitory peptide. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption><graphic xlink:href="zbc0290841690007"/></fig>
###xml 504 532 <span type="species:ncbi:12721">human immunodeficiency virus</span>
FIGURE 7.The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis.A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without alpha-Me-5HT (20 mum, 3 min) in the absence or presence of the cell-permeable (myristoylated) or non-permeable dynamin inhibitory peptide (both 50 mum), or a cell-permeable scrambled control peptide (50 mum). This scrambled peptide was fused with the protein transduction domain of the human immunodeficiency virus TAT protein (YGRKKRRQRRR, 53), which rendered it cell-permeable. All peptides were added 30 min before alpha-Me-5HT treatment. B, quantification of phospho-ERK under different conditions. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 mum) in the presence of alpha-Me-5HT (20 mum) in cells dialyzed with the dynamin inhibitory peptide (50 mum) or a scrambled control peptide (50 mum). Inset, representative traces of NMDAR-EPSC taken at time points denoted by #. Scale bars: 100 pA, 10 ms. D, cumulative data (mean +/- S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of alpha-Me-5HT in neurons injected with or without the dynamin inhibitory peptide. *, p < 0.001, ANOVA.
###end p 42
###begin p 43
###xml 32 36 32 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 123 0 123 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The counteractive effect of 5-HT<sub>2A/C</sub> on 5-HT<sub>1A</sub> regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis.</bold>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 228 229 223 224 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 358 359 352 353 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 414 415 407 408 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 651 652 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 717 722 706 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 783 784 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 801 802 788 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 877 878 863 864 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 918 919 899 900 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 981 982 961 962 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1021 1022 1000 1001 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1025 1030 1004 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 1103 1113 1082 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 1130 1131 1109 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1343 1344 1316 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 495 523 <span type="species:ncbi:12721">human immunodeficiency virus</span>
The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis.A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without alpha-Me-5HT (20 mum, 3 min) in the absence or presence of the cell-permeable (myristoylated) or non-permeable dynamin inhibitory peptide (both 50 mum), or a cell-permeable scrambled control peptide (50 mum). This scrambled peptide was fused with the protein transduction domain of the human immunodeficiency virus TAT protein (YGRKKRRQRRR, 53), which rendered it cell-permeable. All peptides were added 30 min before alpha-Me-5HT treatment. B, quantification of phospho-ERK under different conditions. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 mum) in the presence of alpha-Me-5HT (20 mum) in cells dialyzed with the dynamin inhibitory peptide (50 mum) or a scrambled control peptide (50 mum). Inset, representative traces of NMDAR-EPSC taken at time points denoted by #. Scale bars: 100 pA, 10 ms. D, cumulative data (mean +/- S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of alpha-Me-5HT in neurons injected with or without the dynamin inhibitory peptide. *, p < 0.001, ANOVA.
###end p 43
###begin p 44
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The</italic>
###xml 83 84 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 102 104 99 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 8 133 5 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-mediated Pathway Is Involved in the Counteractive Effects of 5-HT<sub>2</sub> Receptors on 5-HT<sub>1A</sub> Regulation of NMDAR Currents</italic>
###xml 201 202 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 464 466 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 468 470 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 509 510 503 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 687 688 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 681 688 669 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 960 961 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 954 961 926 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 1057 1058 1029 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The beta-Arrestin-mediated Pathway Is Involved in the Counteractive Effects of 5-HT2 Receptors on 5-HT1A Regulation of NMDAR Currents-Next, we sought to identify the signaling mechanism underlying 5-HT2 activation of ERK. Recently, it has been shown that some G proteins form a signaling complex with the multifunctional adaptor and transducer molecule, beta-arrestins 1/2, which recruits and activates components of the mitogen-activated protein kinase cascades (31, 32). To examine the possibility that 5-HT2 receptors activate ERK through the beta-arrestin pathway, we transfected PFC cultures with siRNA against beta-arrestin1 or -2 to knock down their expression. As shown in Fig. 6A, the protein level of beta-arrestin1 or -2 was selectively reduced by beta-arrestin1 siRNA or beta-arrestin2 siRNA, respectively, but not by a scrambled siRNA. The alpha-Me-5HT-induced activation of ERK1/2 was markedly blocked by knockdown of beta-arrestin1 or -2 (Fig. 6B). The total ERK level was not affected among all experimental conditions. It suggests that 5-HT2 receptors activate ERK through a mechanism depending on beta-arrestins.
###end p 44
###begin p 45
###xml 85 87 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 169 170 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 237 238 234 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 246 248 243 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 572 573 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 627 628 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 683 684 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 960 961 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 954 961 922 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 1000 1001 963 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1013 1014 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1007 1014 970 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 1053 1054 1011 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1129 1130 1085 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1241 1242 1194 1195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1250 1252 1203 1205 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
beta-Arrestin is highly expressed in postsynaptic synapses of glutamatergic neurons (33), where both 5-HT receptors and NMDA receptors are abundant. To test whether 5-HT2 activation of ERK is required for the counteracting effect of 5-HT2 on 5-HT1A modulation of NMDAR channels, we examined the effect of 8-OH-DPAT on NMDAR currents in the presence of alpha-Me-5HT in PFC cultures transfected with siRNA against beta-arrestin1 or -2. No significant differences in NMDAR current densities were found in neurons with different transfections (GFP: 20.1 +/- 1.3 pA/picofarad, n = 11; beta-arrestin1 siRNA: 20 +/- 1.2 pA/picofarad, n = 7; beta-arrestin2 siRNA: 19.5 +/- 0.8 pA/picofarad, n = 11). In addition, the effect of 8-OH-DPAT on NMDAR currents was the same in all experimental groups. However, alpha-Me-5HT failed to counteract the 8-OH-DPAT reduction of NMDAR currents in GFP-positive neurons transfected with beta-arrestin1 or beta-arrestin2 siRNA (Fig. 6C: beta-arrestin1 siRNA: 20.3 +/- 1.4%, n = 7; Fig. 6D: beta-arrestin2 siRNA: 20.0 +/- 1.1%, n = 11), as compared with neurons transfected with GFP alone (7.4 +/- 1.2%; n = 11). Taken together, these data suggest that beta-arrestins are involved in the counteractive effect of 5-HT2 on 5-HT1A regulation of NMDAR currents in PFC neurons.
###end p 45
###begin p 46
###xml 148 150 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 228 229 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 237 239 234 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 436 438 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 461 462 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 467 468 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 453 469 450 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 (<italic>A</italic> and <italic>B</italic>)</xref>
###xml 558 559 554 555 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 817 818 808 809 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 863 865 850 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 906 907 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 921 922 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 927 928 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 913 928 898 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, <italic>C</italic> and <italic>D</italic></xref>
###xml 984 985 969 970 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1026 1027 1011 1012 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1054 1055 1039 1040 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1072 1074 1057 1059 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
Because dynamin-dependent endocytosis of G protein-coupled receptor is required for G protein-coupled receptor/beta-arrestin-induced ERK signaling (34), we further examined the role of dynamin in the counteractive effect of 5-HT2 on 5-HT1A regulation of NMDAR currents. PFC cultures were treated with a dynamin inhibitory peptide, which competes for binding to amphiphysin and hence inhibits the clathrin/dynamin-dependent endocytosis (35). As shown in Fig. 7 (A and B), treatment of PFC cultures with the membrane-permeable dynamin inhibitory peptide (50 mum) markedly blocked the alpha-Me-5HT-induced ERK activation, whereas the membrane-impermeable dynamin inhibitory peptide or a cell-permeable scrambled control peptide was ineffective. Furthermore, in neurons injected with the dynamin inhibitory peptide (50 mum), alpha-Me-5HT failed to counteract the 5-HT1A reduction of NMDAR-EPSC (35.8 +/- 6.3%, n = 5 (Fig. 7, C and D)). Together, these data suggest that dynamin-based 5-HT2 receptor endocytosis is involved in 5-HT2 activation of ERK and 5-HT2 opposing of 5-HT1A regulation of NMDAR currents.
###end p 46
###begin p 47
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 8.</label>
###xml 40 44 40 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 63 65 63 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 9 95 9 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of Src prevents 5-HT<sub>2A/C</sub> from opposing 5-HT<sub>1A</sub> regulation of NMDAR currents.</bold>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 200 201 195 196 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 308 309 302 303 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 356 357 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 422 427 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 488 489 476 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 506 507 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 582 583 569 570 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 623 624 605 606 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 659 660 640 641 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 675 676 655 656 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 679 684 659 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 783 792 763 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scalebars</italic>
###xml 810 811 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 976 977 950 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 993 9 967 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48"><bold>Inhibition of Src prevents 5-HT<sub>2A/C</sub> from opposing 5-HT<sub>1A</sub> regulation of NMDAR currents.</bold><italic>A</italic>, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 &#956;<sc>m</sc>, added 30 min before &#945;-Me-5HT treatment). <italic>B</italic>, quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) in cells injected with PP2 (20 &#956;<sc>m</sc>) or PP3 (20 &#956;<sc>m</sc>). <italic>Inset</italic>, representative traces of NMDAR-EPSC (average of three trials) taken at time points denoted by #. <italic>Scalebars</italic>: 100 pA, 100 ms. <italic>D</italic>, cumulative data (mean &#177; S.E.) showing the percent reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of &#945;-Me-5HT under different conditions. *, <italic>p</italic> &lt; 0.001, ANOVA.</p>
###xml 9 993 9 967 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48"><bold>Inhibition of Src prevents 5-HT<sub>2A/C</sub> from opposing 5-HT<sub>1A</sub> regulation of NMDAR currents.</bold><italic>A</italic>, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 &#956;<sc>m</sc>, added 30 min before &#945;-Me-5HT treatment). <italic>B</italic>, quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) in cells injected with PP2 (20 &#956;<sc>m</sc>) or PP3 (20 &#956;<sc>m</sc>). <italic>Inset</italic>, representative traces of NMDAR-EPSC (average of three trials) taken at time points denoted by #. <italic>Scalebars</italic>: 100 pA, 100 ms. <italic>D</italic>, cumulative data (mean &#177; S.E.) showing the percent reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of &#945;-Me-5HT under different conditions. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption>
###xml 993 993 967 967 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690008"/>
###xml 0 993 0 967 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig8"><label>FIGURE 8.</label><caption><p textid="48"><bold>Inhibition of Src prevents 5-HT<sub>2A/C</sub> from opposing 5-HT<sub>1A</sub> regulation of NMDAR currents.</bold><italic>A</italic>, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without &#945;-Me-5HT (20 &#956;<sc>m</sc>, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 &#956;<sc>m</sc>, added 30 min before &#945;-Me-5HT treatment). <italic>B</italic>, quantification of phospho-ERK under different conditions. Each <italic>point</italic> represents mean &#177; S.E. of 4&#8211;5 independent experiments. *, <italic>p</italic> &lt; 0.001, ANOVA. <italic>C</italic>, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 &#956;<sc>m</sc>) in the presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>) in cells injected with PP2 (20 &#956;<sc>m</sc>) or PP3 (20 &#956;<sc>m</sc>). <italic>Inset</italic>, representative traces of NMDAR-EPSC (average of three trials) taken at time points denoted by #. <italic>Scalebars</italic>: 100 pA, 100 ms. <italic>D</italic>, cumulative data (mean &#177; S.E.) showing the percent reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of &#945;-Me-5HT under different conditions. *, <italic>p</italic> &lt; 0.001, ANOVA.</p></caption><graphic xlink:href="zbc0290841690008"/></fig>
FIGURE 8.Inhibition of Src prevents 5-HT2A/C from opposing 5-HT1A regulation of NMDAR currents.A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without alpha-Me-5HT (20 mum, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 mum, added 30 min before alpha-Me-5HT treatment). B, quantification of phospho-ERK under different conditions. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 mum) in the presence of alpha-Me-5HT (20 mum) in cells injected with PP2 (20 mum) or PP3 (20 mum). Inset, representative traces of NMDAR-EPSC (average of three trials) taken at time points denoted by #. Scalebars: 100 pA, 100 ms. D, cumulative data (mean +/- S.E.) showing the percent reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of alpha-Me-5HT under different conditions. *, p < 0.001, ANOVA.
###end p 47
###begin p 48
###xml 31 35 31 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of Src prevents 5-HT<sub>2A/C</sub> from opposing 5-HT<sub>1A</sub> regulation of NMDAR currents.</bold>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 191 192 186 187 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 299 300 293 294 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 347 348 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 413 418 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">point</italic>
###xml 479 480 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 497 498 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 573 574 560 561 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 614 615 596 597 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 650 651 631 632 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 666 667 646 647 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 670 675 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 774 783 754 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scalebars</italic>
###xml 801 802 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 967 968 941 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Inhibition of Src prevents 5-HT2A/C from opposing 5-HT1A regulation of NMDAR currents.A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without alpha-Me-5HT (20 mum, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 mum, added 30 min before alpha-Me-5HT treatment). B, quantification of phospho-ERK under different conditions. Each point represents mean +/- S.E. of 4-5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 mum) in the presence of alpha-Me-5HT (20 mum) in cells injected with PP2 (20 mum) or PP3 (20 mum). Inset, representative traces of NMDAR-EPSC (average of three trials) taken at time points denoted by #. Scalebars: 100 pA, 100 ms. D, cumulative data (mean +/- S.E.) showing the percent reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of alpha-Me-5HT under different conditions. *, p < 0.001, ANOVA.
###end p 48
###begin p 49
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 216 217 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 272 273 272 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 281 283 281 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 432 433 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 438 439 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 424 440 420 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 (<italic>A</italic> and <italic>B</italic>)</xref>
###xml 467 468 462 463 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 509 510 503 504 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 790 791 776 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 784 791 770 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8<italic>C</italic></xref>
###xml 813 814 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 826 827 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 820 827 804 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8<italic>D</italic></xref>
###xml 848 849 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 940 941 922 923 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Previous studies have suggested that Src-mediated tyrosine phosphorylation of dynamin is involved in G protein-coupled receptor-induced ERK signaling (31, 36). To test whether Src kinase activity is required for 5-HT2 activation of ERK and the counteractive effect of 5-HT2 on 5-HT1A regulation of NMDAR currents, we measured the effect of alpha-Me-5HT in PFC neurons treated with the Src kinase inhibitor, PP2. As shown in Fig. 8 (A and B), application of PP2 (20 mum), but not the inactive analog PP3 (20 mum), significantly blocked the alpha-Me-5HT-induced ERK phosphorylation. The total ERK level was not affected in cells subjected to different treatments. Moreover, in the presence of PP2, but not PP3, alpha-Me-5HT lost the ability to oppose 8-OH-DPAT reduction of NMDAR-EPSC (Fig. 8C: PP2: 32.7 +/- 3.7%, n = 7; Fig. 8D: PP3: 8.8 +/- 3.3%, n = 4). Taken together, these results suggest that Src kinase activation is involved in 5-HT2 signaling.
###end p 49
###begin p 50
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 42 44 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 84 0 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2</sub> Receptors Opposes 5-HT<sub>1A</sub> Reduction of Surface NR2B Subunits in a</italic>
###xml 89 115 86 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-dependent Manner</italic>
###xml 123 125 120 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 134 138 131 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 675 677 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 711 712 707 708 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 805 806 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 811 812 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 797 812 793 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9, <italic>A</italic> and <italic>B</italic></xref>
###xml 907 913 900 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 997 998 984 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1011 1017 998 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 1035 1036 1019 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1066 1067 1050 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1060 1067 1044 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9<italic>G</italic></xref>
###xml 1104 1105 1083 1084 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1274 1275 1247 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1285 1286 1258 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1291 1292 1264 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1277 1292 1250 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9, <italic>C</italic> and <italic>G</italic></xref>
###xml 1566 1567 1535 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1560 1567 1529 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9<italic>G</italic></xref>
Activation of 5-HT2 Receptors Opposes 5-HT1A Reduction of Surface NR2B Subunits in a beta-Arrestin-dependent Manner-If 5-HT1A and 5-HT2A/C regulate microtubule dynamics in a counteractive manner, it is possible that they may alter NMDAR trafficking on microtubules in an opposite way. To test this, we performed immunocytochemical experiments in cultured PFC neurons transfected with GFP-tagged NR2B subunits (the GFP tag is positioned at the extracellular N terminus of NR2B). Surface NR2B receptors were detected with the anti-GFP primary antibody, followed by rhodamine-conjugated secondary antibody in non-permeabilized conditions. Consistent with our previous findings (21), application of 8-OH-DPAT (40 mum, 5 min), caused a marked reduction in the number and size of surface NR2B clusters (Fig. 9, A and B), as compared with control neurons (cluster density: 43.6 +/- 1.7 clusters/50 mum in controls versus 22.7 +/- 0.8 clusters/50 mum in DPAT-treated cells; cluster size: 0.33 +/- 0.02 mum2 in controls versus 0.18 +/- 0.02 mum2 in DPAT-treated cells (Fig. 9G). Treatment with alpha-Me-5HT (40 mum, 30 min) significantly prevented the 8-OH-DPAT-induced reduction of surface NR2B subunits (cluster density: 40.0 +/- 2.7 clusters/50 mum; cluster size: 0.3 +/- 0.03 mum2 (Fig. 9, C and G)). The alpha-Me-5HT treatment itself did not affect the distribution of surface NR2B clusters (data not shown). The fluorescence intensity of surface NR2B clusters (average gray value per pixel) was not significantly changed in neurons subject to various treatments (Fig. 9G). The total amount of recombinant NR2B receptor (GFP channel) was unaltered.
###end p 50
###begin p 51
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 76 78 76 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 236 237 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 242 243 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 228 244 225 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 (<italic>D</italic> and <italic>E</italic>)</xref>
###xml 419 420 407 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 428 429 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 422 429 410 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9<italic>G</italic></xref>
###xml 564 565 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 573 574 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 567 574 549 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9<italic>G</italic></xref>
###xml 801 802 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 812 813 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 818 819 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 804 819 773 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9, <italic>F</italic> and <italic>G</italic></xref>
###xml 868 869 837 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 892 894 861 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
Next, we examined the signaling molecules involved in 5-HT2 blockade of 5-HT1A reduction of surface NR2B clusters. To test this, we co-transfected PFC cultures with beta-arrestin2 siRNA and GFP-tagged NR2B subunits. As shown in Fig. 9 (D and E), transfection of beta-arrestin2 alone did not affect the distribution of surface NR2B clusters (cluster density: 38.1 +/- 3.1 clusters/50 mum; cluster size: 0.29 +/- 0.01 mum2 (Fig. 9G)) or the reducing effect of 8-OH-DPAT on NR2B clusters (cluster density: 22.8 +/- 0.8 clusters/50 mum; cluster size: 0.16 +/- 0.03 mum2 (Fig. 9G)). However, knockdown of beta-arrestin2 prevented alpha-Me-5HT from blocking the 8-OH-DPAT-induced reduction of surface NR2B clusters on dendrites (cluster density: 23.4 +/- 1.6 clusters/50 mum; cluster size: 0.17 +/- 0.02 mum2 (Fig. 9, F and G)). These results suggest that activation of 5-HT2 receptors opposes 5-HT1A reduction of the surface NR2B level through a beta-arrestin-dependent mechanism.
###end p 51
###begin p 52
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 716 717 716 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 722 723 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 707 724 707 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig10" ref-type="fig">Fig. 10 (<italic>A</italic> and <italic>B</italic>)</xref>
###xml 889 890 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1049 1053 1045 1049 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1132 1133 1124 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1199 1201 1191 1193 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1280 1281 1268 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1304 1305 1292 1293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 1311 1312 1296 1297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1537 1544 1522 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1557 1559 1542 1544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1568 1572 1553 1557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
Finally, we tested whether the change on NMDAR-EPSC amplitudes in PFC neurons by acute fluoxetine treatment of intact animals can be accounted for by the altered number of NMDA receptors on the cell membrane. Surface biotinylation experiments (23) were performed to measure levels of surface NR1 and NR2B in PFC slices from animals intraperitoneally injected with fluoxetine (20 mg/kg). Surface proteins were labeled with Sulfo-NHS-LC-biotin, and then biotinylated surface proteins were separated from non-labeled intracellular proteins by reaction with NeutrAvidin beads. Surface and total proteins were subjected to electrophoresis and probed with an antibody against the NR1 or NR2B subunit. As shown in Fig. 10 (A and B), the surface levels of NR1 and NR2B in PFC slices were significantly lower in animals exposed to fluoxetine (NR1: 70 +/- 3% of control; NR2B: 60 +/- 6% of control; n = 4). Consistent with electrophysiological results, the fluoxetine-induced reduction of surface NMDARs was more prominent in animals co-injected with the 5-HT2A/C antagonist ketanserin (NR1: 29 +/- 3% of control; NR2B: 30 +/- 1% of control; n = 4) and was largely blocked in animals co-injected with the 5-HT1A antagonist WAY-100635 (NR1: 82 +/- 5% of control; NR2B: 84 +/- 1% of control; n = 4). The surface GABAAR beta2 subunit level, as well as the total NR1 or NR2B level, in PFC slices was unchanged by any of these drug administrations. Taken together, these results suggest that endogenous serotonin regulates PFC NMDAR surface expression in vivo through 5-HT1A and 5-HT2A/C receptors in a counteractive manner.
###end p 52
###begin p 53
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 9.</label>
###xml 27 31 27 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 58 60 58 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 9 126 9 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors opposes the 5-HT<sub>1A</sub> -induced decrease of surface NR2B clusters on neuronal dendrites.</bold>
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;F</italic>
###xml 317 318 313 314 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 376 377 367 368 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 421 438 412 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Enlarged versions</italic>
###xml 446 459 437 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">boxed regions</italic>
###xml 511 512 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 651 652 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 667 9 658 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54"><bold>Activation of 5-HT<sub>2A/C</sub> receptors opposes the 5-HT<sub>1A</sub> -induced decrease of surface NR2B clusters on neuronal dendrites.</bold><italic>A&#8211;F</italic>, immunocytochemical images of surface GFP-NR2B clusters in PFC cultures transfected with or without&#946;-arrestin2 siRNA. Cultures were untreated (control) or treated with 8-OH-DPAT (40 &#956;<sc>m</sc>, 5 min) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, added 10 min before 8-OH-DPAT treatment). <italic>Enlarged versions</italic> of the <italic>boxed regions</italic> of dendrites are shown beneath each of the images. <italic>G</italic>, quantitative analysis of surface GFP-NR2B clusters (cluster density, size, and intensity) along dendrites under different treatments. *, <italic>p</italic> &lt; 0.01, ANOVA.</p>
###xml 9 667 9 658 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="54"><bold>Activation of 5-HT<sub>2A/C</sub> receptors opposes the 5-HT<sub>1A</sub> -induced decrease of surface NR2B clusters on neuronal dendrites.</bold><italic>A&#8211;F</italic>, immunocytochemical images of surface GFP-NR2B clusters in PFC cultures transfected with or without&#946;-arrestin2 siRNA. Cultures were untreated (control) or treated with 8-OH-DPAT (40 &#956;<sc>m</sc>, 5 min) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, added 10 min before 8-OH-DPAT treatment). <italic>Enlarged versions</italic> of the <italic>boxed regions</italic> of dendrites are shown beneath each of the images. <italic>G</italic>, quantitative analysis of surface GFP-NR2B clusters (cluster density, size, and intensity) along dendrites under different treatments. *, <italic>p</italic> &lt; 0.01, ANOVA.</p></caption>
###xml 667 667 658 658 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690009"/>
###xml 0 667 0 658 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig9"><label>FIGURE 9.</label><caption><p textid="54"><bold>Activation of 5-HT<sub>2A/C</sub> receptors opposes the 5-HT<sub>1A</sub> -induced decrease of surface NR2B clusters on neuronal dendrites.</bold><italic>A&#8211;F</italic>, immunocytochemical images of surface GFP-NR2B clusters in PFC cultures transfected with or without&#946;-arrestin2 siRNA. Cultures were untreated (control) or treated with 8-OH-DPAT (40 &#956;<sc>m</sc>, 5 min) in the absence or presence of &#945;-Me-5HT (20 &#956;<sc>m</sc>, added 10 min before 8-OH-DPAT treatment). <italic>Enlarged versions</italic> of the <italic>boxed regions</italic> of dendrites are shown beneath each of the images. <italic>G</italic>, quantitative analysis of surface GFP-NR2B clusters (cluster density, size, and intensity) along dendrites under different treatments. *, <italic>p</italic> &lt; 0.01, ANOVA.</p></caption><graphic xlink:href="zbc0290841690009"/></fig>
FIGURE 9.Activation of 5-HT2A/C receptors opposes the 5-HT1A -induced decrease of surface NR2B clusters on neuronal dendrites.A-F, immunocytochemical images of surface GFP-NR2B clusters in PFC cultures transfected with or withoutbeta-arrestin2 siRNA. Cultures were untreated (control) or treated with 8-OH-DPAT (40 mum, 5 min) in the absence or presence of alpha-Me-5HT (20 mum, added 10 min before 8-OH-DPAT treatment). Enlarged versions of the boxed regions of dendrites are shown beneath each of the images. G, quantitative analysis of surface GFP-NR2B clusters (cluster density, size, and intensity) along dendrites under different treatments. *, p < 0.01, ANOVA.
###end p 53
###begin p 54
###xml 18 22 18 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 117 0 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of 5-HT<sub>2A/C</sub> receptors opposes the 5-HT<sub>1A</sub> -induced decrease of surface NR2B clusters on neuronal dendrites.</bold>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;F</italic>
###xml 308 309 304 305 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 367 368 358 359 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 412 429 403 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Enlarged versions</italic>
###xml 437 450 428 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">boxed regions</italic>
###xml 502 503 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 642 643 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Activation of 5-HT2A/C receptors opposes the 5-HT1A -induced decrease of surface NR2B clusters on neuronal dendrites.A-F, immunocytochemical images of surface GFP-NR2B clusters in PFC cultures transfected with or withoutbeta-arrestin2 siRNA. Cultures were untreated (control) or treated with 8-OH-DPAT (40 mum, 5 min) in the absence or presence of alpha-Me-5HT (20 mum, added 10 min before 8-OH-DPAT treatment). Enlarged versions of the boxed regions of dendrites are shown beneath each of the images. G, quantitative analysis of surface GFP-NR2B clusters (cluster density, size, and intensity) along dendrites under different treatments. *, p < 0.01, ANOVA.
###end p 54
###begin p 55
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 192 194 192 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
NR1 and NR2 subunits have to be co-assembled before leaving the endoplasmic reticulum and being transported along microtubules in dendrites to synapses. Our previous study (21) shows that 5-HT1A receptors primarily target NR2B subunit-containing NMDA receptors, consistent with NR2B being the cargo of the microtubule motor KIF17. With the application of fluoxetine plus ketanserin, the surface levels of NR1 and NR2B were reduced to a similar degree (surface NR2A was also reduced, data not shown). It suggests that this reduction likely results from endogenous NR1/NR2B heteromers and NR1/NR2A/NR2B triheteromers.
###end p 55
###begin title 56
DISCUSSION
###end title 56
###begin p 57
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 474 475 474 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 484 485 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 523 524 523 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 556 558 556 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 830 832 830 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 877 881 877 881 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
It is well known that many antidepressants and antipsychotics exert their actions by inhibiting serotonin reuptake and thus enhance serotonergic transmission (37, 38). Because serotonin has multiple receptor subtypes, systemic elevation of serotonin can induce diverse physiological effects in neurons (2). The molecular mechanisms for serotonin to regulate cellular targets through different subtypes of receptors remain to be identified. We have previously found that 5-HT2 and 5-HT4 receptors are linked to regulate GABAA receptors (9, 39), whereas 5-HT1A receptors are linked to regulate NMDA receptors in PFC neurons (21). The specific coupling of different 5-HT receptors to distinct ion channels allows serotonin to regulate multiple targets in a precise but flexible manner. Here, we provide evidence showing that the 5-HT1A regulation of NMDARs can be modified by 5-HT2A/C receptor activation, which provides a mechanism to fine-tune the effect of serotonin on NMDAR-mediated synaptic transmission and plasticity.
###end p 57
###begin p 58
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 312 313 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 322 323 322 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 423 424 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 589 590 589 590 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 689 691 689 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 700 702 700 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 1086 1090 1086 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1128 1130 1128 1130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1187 1189 1187 1189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1198 1202 1198 1202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 1339 1340 1339 1340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1346 1347 1346 1347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1467 1469 1467 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref44">44</xref>
Under normal physiological conditions, which of the one or more 5-HT receptors in PFC pyramidal neurons that are activated by serotonin is determined by the serotonergic projection from dorsal raphe to cellular compartments rich in different subtypes of receptors (40). Agonist binding studies indicate that 5-HT1 and 5-HT2 receptors have different affinities (nanomolar versus low micromolar) to 5-HT, suggesting that 5-HT1 receptor activation may play a dominant role in response to serotonin. Microdialysis studies have shown that synaptic concentration of serotonin can reach up to 6 mm (41), suggesting that sometimes all 5-HT receptors could be fully activated at synapses. Both 5-HT1A and 5-HT2A receptors are expressed at dendritic shafts and spines of PFC pyramidal neurons (42, 43), where NMDA receptors are abundant, prompting us to speculate that both receptors may interact with NMDA receptors in synergistic or opposite ways. Our studies in PFC pyramidal neurons from both acute slices and intact animals treated with various 5-HT-related drugs indicate that blocking 5-HT2A/C receptors unmasks the ability of 5-HT1A receptors to reduce NMDAR currents, suggesting that 5-HT1A and 5-HT2A/C receptors converge on NMDAR channels in a counteractive manner. Similar to serotonin, it has been shown that, in response to dopamine, D1 and D2 receptors that are linked to distinct signaling cascades regulate cortical GABAergic inhibition in an opposing manner (44).
###end p 58
###begin p 59
###xml 0 10 0 10 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 10.</label>
###xml 10 85 10 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The surface NMDAR level is reduced in PFC from fluoxetine-injected animals.</bold>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 159 160 159 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 397 398 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 501 502 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 515 516 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 10 532 10 529 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="60"><bold>The surface NMDAR level is reduced in PFC from fluoxetine-injected animals.</bold><italic>A</italic>, Western blot analysis showing the surface and total NR1, NR2B, and GABA<sub>A</sub>R &#946;2 subunits in lysates of PFC slices taken from animals receiving a single intraperitoneal injection of saline, fluoxetine, ketanserin, ketanserin plus fluoxetine, WAY-100635, or WAY-100635 plus fluoxetine (all drugs are 20 mg/kg). <italic>B</italic>, quantification of surface NMDAR subunits in PFC slices from animals treated with different drugs. *, <italic>p</italic> &lt; 0.01; **, <italic>p</italic> &lt; 0.001; ANOVA.</p>
###xml 10 532 10 529 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="60"><bold>The surface NMDAR level is reduced in PFC from fluoxetine-injected animals.</bold><italic>A</italic>, Western blot analysis showing the surface and total NR1, NR2B, and GABA<sub>A</sub>R &#946;2 subunits in lysates of PFC slices taken from animals receiving a single intraperitoneal injection of saline, fluoxetine, ketanserin, ketanserin plus fluoxetine, WAY-100635, or WAY-100635 plus fluoxetine (all drugs are 20 mg/kg). <italic>B</italic>, quantification of surface NMDAR subunits in PFC slices from animals treated with different drugs. *, <italic>p</italic> &lt; 0.01; **, <italic>p</italic> &lt; 0.001; ANOVA.</p></caption>
###xml 532 532 529 529 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0290841690010"/>
###xml 0 532 0 529 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig10"><label>FIGURE 10.</label><caption><p textid="60"><bold>The surface NMDAR level is reduced in PFC from fluoxetine-injected animals.</bold><italic>A</italic>, Western blot analysis showing the surface and total NR1, NR2B, and GABA<sub>A</sub>R &#946;2 subunits in lysates of PFC slices taken from animals receiving a single intraperitoneal injection of saline, fluoxetine, ketanserin, ketanserin plus fluoxetine, WAY-100635, or WAY-100635 plus fluoxetine (all drugs are 20 mg/kg). <italic>B</italic>, quantification of surface NMDAR subunits in PFC slices from animals treated with different drugs. *, <italic>p</italic> &lt; 0.01; **, <italic>p</italic> &lt; 0.001; ANOVA.</p></caption><graphic xlink:href="zbc0290841690010"/></fig>
FIGURE 10.The surface NMDAR level is reduced in PFC from fluoxetine-injected animals.A, Western blot analysis showing the surface and total NR1, NR2B, and GABAAR beta2 subunits in lysates of PFC slices taken from animals receiving a single intraperitoneal injection of saline, fluoxetine, ketanserin, ketanserin plus fluoxetine, WAY-100635, or WAY-100635 plus fluoxetine (all drugs are 20 mg/kg). B, quantification of surface NMDAR subunits in PFC slices from animals treated with different drugs. *, p < 0.01; **, p < 0.001; ANOVA.
###end p 59
###begin p 60
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The surface NMDAR level is reduced in PFC from fluoxetine-injected animals.</bold>
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 387 388 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 491 492 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 505 506 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
The surface NMDAR level is reduced in PFC from fluoxetine-injected animals.A, Western blot analysis showing the surface and total NR1, NR2B, and GABAAR beta2 subunits in lysates of PFC slices taken from animals receiving a single intraperitoneal injection of saline, fluoxetine, ketanserin, ketanserin plus fluoxetine, WAY-100635, or WAY-100635 plus fluoxetine (all drugs are 20 mg/kg). B, quantification of surface NMDAR subunits in PFC slices from animals treated with different drugs. *, p < 0.01; **, p < 0.001; ANOVA.
###end p 60
###begin p 61
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 241 245 241 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 282 284 282 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 425 427 425 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 436 440 436 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
Our previous study has shown that activation of 5-HT1A receptors suppresses NMDAR currents by reducing microtubule stability and the ensuing NMDAR trafficking along dendritic microtubules (21). In this study, we found that activation of 5-HT2A/C receptor opposes the ability of 5-HT1A to induce microtubule depolymerization, suggesting that microtubule dynamics and the microtubule-based NMDAR transport are regulated by 5-HT1A and 5-HT2A/C receptors in a counteractive fashion.
###end p 61
###begin p 62
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 390 392 390 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 566 568 566 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 577 581 577 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 758 762 758 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
The stability of microtubules is regulated by different microtubule-associated proteins (MAPs) in distinct neuronal compartments. The phosphorylation state of MAP2, a dendrite-specific MAP, determines the ability of MAP2 to associate and stabilize dendritic microtubules (45). One key signaling molecule that regulates MAP2 phosphorylation is ERK (28). Our previous study suggests that 5-HT1A activation suppresses ERK activity, which leads to the decreased MAP2 phosphorylation, MAP2-microtubule interaction, and microtubule stability (21). It is possible that 5-HT1A and 5-HT2A/C oppositely regulates ERK activity, thereby controlling microtubule stability in a counteractive manner. Consistently, our biochemical and immunocytochemical data show that 5-HT2A/C activation potently enhances ERK activity in the dendrites of PFC cultures.
###end p 62
###begin p 63
###xml 17 21 17 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 384 386 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 388 390 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 397 399 394 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 452 454 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref46">46</xref>
###xml 478 480 472 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 647 651 635 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 727 731 715 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 739 741 727 729 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 806 810 794 798 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 928 930 916 918 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1026 1028 1011 1013 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
How does the 5-HT2A/C receptor activate ERK? Phospholipase C and inositol 1,4,5-trisphosphate, two downstream molecules of classic 5-HT2 signaling, are not involved in this regulation (data not shown). Recent studies have suggested that the scaffolding protein beta-arrestin, which binds to the third intracellular loop of certain G protein-coupled receptors, induces ERK activation (31, 32). 5-HT2A receptors are found to bind purified beta-arrestin (46). However, whether 5-HT2A activates mitogen-activated protein kinase via beta-arrestin pathway is essentially unknown. Our data show that knockdown of beta-arrestin1/2 not only blocks the 5-HT2A/C-induced ERK activation but also eliminates the counteractive effect of 5-HT2A/C on 5-HT1A reduction of NMDAR currents. In addition, we found that the 5-HT2A/C action is dependent on Src activation and clarthin/dynamin-mediated endocytosis of the receptor. Taken together, 5-HT2A, via the beta-arrestin/Src/dynamin cascade, induces ERK activation to oppose the effect of 5-HT1A on NMDAR functions.
###end p 63
###begin p 64
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref50">50</xref>
###xml 289 291 289 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref51">51</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref52">52</xref>
###xml 519 521 519 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 598 602 598 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 632 634 632 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 643 647 643 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 701 705 701 705 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 722 724 722 724 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 853 857 847 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
###xml 872 874 866 868 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
Several mechanisms have been proposed for the regulation of NMDAR functions, including altering the phosphorylation state and biophysical properties of the channel (47, 48) and changing NMDAR trafficking and channel numbers at the membrane (49, 50). Our previous finding suggests that 5-HT1A decreases surface NR2B clusters in a microtubule-dependent manner (21), consistent with the role of cytoskeleton-based transport on NMDAR insertion to the plasma membrane (51, 52). Our immunocytochemical data show that the 5-HT1A reduction of surface NR2B clusters is attenuated by pretreatment with a 5-HT2A/C agonist, confirming that 5-HT1A and 5-HT2A/C oppositely regulate NMDAR trafficking. Moreover, 5-HT2A/C opposes the 5-HT1A reduction of surface NR2B clusters in a beta-arrestin-dependent manner, consistent with the beta-arrestin dependence of the 5-HT2A/C action on 5-HT1A regulation of NMDAR currents. Surface biotinylation experiments using PFC from intact animals subject to acute fluoxetine treatment have also confirmed the results found in cultured neurons.
###end p 64
###begin p 65
###xml 86 88 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 97 101 97 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A/C</sub>
Based on the experimental data, we speculate that, in response to serotonin, both 5-HT1A and 5-HT2A/C receptors localized in PFC pyramidal neurons are activated, which converge to regulate NMDAR trafficking and function in an opposite manner, by coupling to distinct signaling cascades and differentially affecting microtubule stability. This study may provide significant insights into the complex regulation of NMDAR-mediated synaptic transmission and plasticity by different serotonin receptors in the PFC network.
###end p 65
###begin p 66
We thank Xiaoqing Chen for technical support.
###end p 66
###begin p 67
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 60 61 60 61 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 273 274 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 335 336 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 395 396 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 416 417 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 463 464 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
The abbreviations used are: 5-HT, serotonin; NMDA, N-methyl-d-aspartate; NMDAR, NMDA receptor; MAP, microtubule-associated protein; MAP2, microtubule-associated protein 2; PFC, prefrontal cortex; ERK, extracellular signal-regulated kinase; ANOVA, analysis of variance; GABAA, gamma-aminobutyric acid, type A; 8-OH-DPAT, 8-hydroxy-2(di-n-propylamino)-tetralin; PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; PP3, 4-amino-7-phenylpyrazol[3,4-d]pyrimidine; siRNA, small interference RNA; GFP, green fluorescent protein; MES, 4-morpholineethanesulfonic acid; fluox, fluoxetine; ket, ketanserin; alpha-Me-5HT, alpha-methyl-5-hydroxytryptamine maleate; EPSC, excitatory postsynaptic current.
###end p 67

